. Since its inception, this series of yearly meetings has continued to emphasize the molecular aspects of toxicity, carcinogenesis, cancer prevention and cancer therapy and the relationships among the four as they relate to human risk.
Transcriptional activator proteins bind to specific enhancer elements in the promoter regions of genes and recruit coactivator proteins to assist in the remodeling of chromatin and the recruitment of RNA polymerase. Two general classes of chromatin-remodeling coactivators have been described: those that alter DNA-nucleosome interactions through ATP hydrolysis, and those which catalyze histone modifications such as acetylation, phosphorylation, and methylation. Individual modifications, or combinations of them, on the N-terminal tails of histones inhibit or promote specific interactions between the histone tail and other proteins. For example, acetylation of lysines reverses chromatin compaction, and thus facilitates transcription by preventing histone tails from one nucleosome from interacting with neighboring nucleosomes; however, lysine acetylation may also recruit proteins which specifically bind the acetylated histones. Some modifications, such as lysine acetylation of various histones and methylation of lysine 4 on histone H3, are generally found in association with chromatin on transcriptionally active promoters. In contrast, methylation of lysine 9 on histone H3 is generally found in association with inactive, tightly compacted chromatin (3, 5) .
Nuclear Receptors and Their Coactivators
The nuclear receptor family is a class of transcriptional activator proteins which has approximately 50 members in mammals, including the receptors for steroid and thyroid hormones, retinoic acid, and vitamin D. Binding of the hormone to the receptor causes a conformational change that allows the DNA-bound receptor to recruit a variety of coactivator proteins to the promoter. One of the major histone modifying coactivator complexes contains a 160-kDa subunit (p160 coactivator) which binds directly to the nuclear receptor; p160 coactivators apparently serve as a scaffold which brings several other coactivator proteins to the promoter, including a histone acetyltransferase (p300, CBP, or p/CAF), and a histone methyltransferase (CARM1) (1, 2) . The mechanism of CARM1's coactivator function and its synergistic cooperation with histone acetyltransferases are the focus of this paper.
CARM1 Is a Histone Methyltransferase
CARM1 belongs to a family of arginine-specific protein methyltransferases, the PRMT family, which transfer a methyl group from S-adenosylmethionine to specific arginine residues of specific target proteins (2) . The protein domain responsible for the methyltransferase activity is highly conserved throughout the family, but each of the currently known 6 family members methylates a different set of proteins. In vitro CARM1 methylates histone H3 on Arg17 and Arg26 (6) . These amino acids lie in the N-terminal tail of histone H3 among sites for lysine acetylation, lysine methylation, and serine phosphorylation. We proposed that the coactivator function of CARM1 may involve its ability to methylate histone H3, and that histone methylation may cooperate with histone acetylation to cause chromatin remodeling.
Synergistic Coactivator Function of CARM1, p300, and p160 Coactivators
The expression of a transiently transfected reporter gene containing an enhancer element that binds a specific nuclear receptor is stimulated when the appropriate nuclear receptor is activated by addition of its cognate hormone. Cotransfection of plasmids encoding 1 of more coactivators may enhance the ability of the nuclear receptor to activate transcription of the reporter gene. When a very low level of the appropriate nuclear receptor is expressed, activation of the reporter gene is almost completely dependent on the cotransfection of plasmids expressing three different coactivators: a p160 coactivator; CARM1; and a histone acetyltransferase (p300, CBP, or p/CAF) (4) . Omission of nuclear receptor, hormone, or any 1 of the 3 coactivators almost completely eliminates reporter gene activity. Under these conditions, the methyltransferase activity of CARM1 is required for its coactivator function, and none of the other protein arginine methyltransferases can substitute for CARM1.
Hormone-Dependent, CARM1-Directed Methylation of Histone H3 In Vivo
Chromatin immunoprecipitation assays demonstrated that CARM1 is recruited to the promoter of steroid hormone regulated genes that are stably integrated into the chromosomes of cultured cells. Furthermore, an antiserum that specifically recognizes the CARM1-methylated form of histone H3 was used to show that methylation of histone H3 by CARM1 also occurred on the same promoters as part of the hormone-stimulated process of transcriptional activation (5) .
The telomeric ends and associated proteins of chromosomes provide both a protective cap against free DNA-initiated, p53-dependent apoptosis and a solution to the DNA "end replication problem" (12) . Evolution has solved the latter problem of the inherent difficulty of DNA polymerases to synthesize the last 50 to 150 base-pairs at the end of each chromosome by using a reverse transcriptase telomerase (TERT) and an RNA template (TR) (1, 6) .
Most normal somatic human cells lack TERT so that telomeres shorten with each cell division, resulting in cellular "crisis" and replicative senescence in vitro. Germ and stem cells are the exceptions. Short telomeres are also associated with organismal aging including premature aging and cancer-prone diseases such as Werner syndrome and dyskeratosis congenita (DC). A haploinsufficiency of TR is responsible for DC (8, 11) . The majority of human cancers maintain their telomeres by inappropriate expression of TERT, whereas 5-10% of human cancers utilize a hyperrecombinogenic mechanism called ALT, alternative lengthening of telomeres (3) .
Animal models of TERT or TR gene knockouts have contributed to our understanding of telomere function. After 4 to 6 generations, TERT−/− or TR−/− mice develop sufficiently shortened telomeres leading to organ failure, eg, increased apoptosis of germ cells and testicular atrophy, and shorter tumor latency (9) . Telomeric dysfunction activates the ATM/p53 pathway. For example, expression of a dominant-negative form of the telomere-associated protein, TRF2, results in chromosomal end-to-end fusions and DNA double-strand breaks (2) by the long established mechanism of breakage-fusion-bridge cycles (7) . These double-strand breaks are repaired by nonhomologous end joining repair (NHEJ) that is error-prone. The lack of chromosomal end-to-end fusions in Ku−/− and TERT−/− double-knockout mice is consistent with an NHEJ repair pathway (4) . p53-mediated apoptosis is the failsafe pathway that also selects rare p53 mutant cells.
T-loops are the ultimate "end game." Griffith et al, first described these Dloop-T-loop structures in the late 1990s (5) and have recently shown that the functional interaction of p53 and TRF2 is the formation and stabilization of T-loops (10) . 
Background
The telomere is a specialized structure at the extremity of all linear chromosomes. Most eukaryotic telomeres are comprised of simple tandem DNA repeat tracts associated with general chromosomal proteins and telomere-specific factors such as TRF1 and TRF2 that are required for the maintenance of chromosomal stability. The 2 conserved features of nearly all eukaryotic telomeres are a long array of repeating 6-8 nucleotide units and a single strand (ss) overhang. This structure should be highly recombinogenic based on studies of homologous recombination catalyzed by RecA protein: such DNA should undergo selfrecombination in which the 3 ss tail strand would invade the internal duplex telomere tracts. Consideration of this led us to propose that mammalian telomeres might be arranged as loops. The biological features of this novel structure would be that it could provide a means of hiding the distal end of the telomere within the internal repeat segments. In a study with the de Lange laboratory (1) we used electron microscopy (EM) to directly visualize loops at the ends of telomeric DNA isolated from human and mouse cells. It was also shown that in vitro TRF2 protein is able to catalyze the formation of looped molecules on a model telomere DNA template. These loops, termed t-loops, have now been found in Oxytrichia, Trypanosome, and pisum sativum (this laboratory, unpublished results) chromosomes. Two immediate questions raised by this study were how looping catalyzed by TRF2 in vitro would depend on the nature of the ss overhang and what other cellular proteins might bind to the t-loop junction.
Dependence of Telomere Looping of the Telomere Terminus
In a recent study (2) a model telomere DNA was constructed consisting of a 3-kb linear plasmid ending with 500 bp of TTAGGG repeats and a 4 base 5 extension that allowed the addition of different ss tails of either 3 or 5 termini. An EM assay was then used to access the frequency of loop formation upon addition of TRF2. DNA templates containing a 54-nt 3 extension of the natural G strand sequence (TTAGGG) were arranged into loops approximately 20% of the time. A variety of termini however showed only a background frequency of looping (∼3%). These included DNA molecules with blunt termini, with any of a variety of 5 extensions, or with termini that were not natural TTAGGG repeats. Variation of the length of the 3 overhang showed that extensions as short as one TTAGGG repeat could promote loop formation. By intermixing telomeric and nontelomeric repeats it was found that loop formation could occur even if the terminal nucleotides of the overhang were not TTAGGG, as long as the sequence at the duplex/ss junction was telomeric. This study led to a model in which we propose that the critical element of the telomeric DNA in loop formation catalyzed by TRF2 is the ss/duplex junction that appears to be specifically recognized by TRF2. Based on this data it was also suggested that TRF2 opens both strands of the telomere terminus allowing both the G rich and C-rich strand to invade.
Interaction of p53 and TRF2 at the t-Loop Junction
Using the previous model telomeric DNA template above, it was possible to ask whether other proteins known to interact with DNA ends or with unusual structures such as the t-loop junction might either block or facilitate t-loop formation by TRF2. One such protein is p53. In studies from other laboratories it had been shown that p53 binds blunt ended DNA and binds ss DNA avidly. We have shown that p53 will bind a number of unusual DNA structures such as 3-stranded and 4-stranded junctions. Using EM (3) it was found that p53 will bind strongly to the natural telomere terminus due to the presence of the ss overhang, but that this does not reflect sequence-specific binding. Further p53 was found to have no affinity for duplex TTAGGG repeats over random sequence DNA. When the model telomere template was incubated with p53 alone, no looping was observed, whereas 20% of the DNA molecules were looped when TRF2 was added (as before). Incubation of the DNA with both proteins led to nearly 30% loop formation irrespective of the order of addition of the proteins. Control experiments suggested that the promotion of loop formation by TRF2 was not due to trivial ss binding activity as several SSBs failed to have any effect. Thus in vivo it is possible that p53 may be involved in the DNA-protein transactions that monitor the telomere status. degradation of most, if not all, short-lived proteins, especially those with growth regulatory properties.
In the latter case, the covalent attachment of ubiquitin to a protein targets it for degradation in the 26S proteasome. The mechanisms by which this happens have been dissected in some detail. In a temporal sense, these include: the activation of ubiquitin by an E1 ubiquitin activating enzyme; transfer of the activated ubiquitin by an E2 ubiquitin conjugating enzyme to an E3 ubiquitin ligase to which the substrate protein is also bound; and then covalent transfer of ubiquitin to the substrate protein. This then targets the ubiquitinilated protein to the 26S proteasome where the protein is degraded and the ubiquitin moiety is recycled. The molecular structure, proteolytic mechanism and regulation of the proteasome is becoming increasingly well understood.
It appears that this means of regulating cellular protein concentrations has arisen relatively recently in evolution. It has the interesting effect of coupling a nonspecific proteolytic activity to specific protein marking by covalent modification. Other layers of regulatory complexity are layered on this by the specific positions and recognitions of ubiquitinylated residues in the substrate protein as well as through the components of the proteasomal complex. All of this raises the intriguing possibility of specifically affecting cellular protein activities and levels by targeting the activity of the process at 1 or several steps. REFERENCES 1. Ciechanover A, Schwatrz AL (1998). The ubiquitin-proteasome pathway:
The complexity and myriad functions of proteins death. The 26S proteasome, a multicatalytic enzyme complex that degrades proteins (8) , plays a critical role in regulating the cell cycle and activating prosurvival pathways, as numerous proteins (or their inhibitors) that regulate these processes are substrates of the proteasome. The proteasome consists of a cylindrical core (20S) capped by 2 19S regulatory units. Ubiquitinated proteins are recognized by the 19S caps, denatured, and fed into the proteolytic core, which consists of 6 proteolytic sites with chymotrypsin-like, trypsin-like, or postglutamyl peptide hydrolytic activity.
Preclinical Activity of PS-341
PS-341, a novel, potent, and selective inhibitor of the proteasome (1), is the first proteasome inhibitor to enter clinical trials. The clinical development program of PS-341 was supported by an extensive preclinical program that showed antitumor activity against pancreatic cancer (3, 13) and colon cancer (5, 9, 11) in combination with standard chemotherapeutic agents or as a singleagent against myeloma (7), prostate cancer (2), and head and neck cancer (14) , among others. Unpublished observations also suggest in vivo activity in mantle cell lymphoma, ovarian cancer, and breast cancer.
Mechanism of Action of Proteasome Inhibition via PS-341
Proteasome inhibition destabilizes the cancer cell via novel molecular mechanisms. There is strong evidence that cell death induced by proteasome inhibition is apoptotic. For example, the cell death observed in multiple myeloma cells exposed to PS-341 involves the activation of caspase-3 and annexin V binding and occurs even in the presence of Bcl-2 (6). Other mechanisms include the prevention of the activation of NF-κB, a transcription factor that promotes several prosurvival pathways important to tumor growth. NF-κB is typically rendered inactive when bound by its inhibitor, IκB. When IκB is degraded by the proteasome, NF-κB translocates to the nucleus, where it initiates the transcription of target genes. Proteasome inhibition stabilizes IκB and prevents the activation of NF-κB in myeloma (7) as well as pancreatic (3) and colon (5) cancers. In addition to its direct activity against cancer cells, proteasome inhibition has been shown to interfere with protective interactions between myeloma cancer cells and the bone marrow, and to restrict tumor-associated angiogenesis.
Clinical Status of PS-341
PS-341 is currently in clinical trials of myeloma and several solid tumors. These trials consist of several trials sponsored by Millennium Pharmaceuticals as well as approximately 20 trials being conducted by the National Cancer Institute. Preliminary phase II data suggest that PS-341 has manageable toxicities and antitumor activity in relapsed/refractory myeloma (10) . A planned phase III trial in myeloma will help clarify the potential of PS-341 in this difficultto-treat disease. Numerous phase I trials of PS-341 used in combination with standard chemotherapeutic agents for the treatment of advanced solid tumors are in progress, the most recent of which have demonstrated that PS-341 can be given with gemcitabine (12) The molecular era of cancer drug design may be viewed as the utilization of our understanding of the molecular pathophisiology and molecular epidemeology of cancer to identify novel and more rational drug discovery targets that will lead to more effective therapeutics. This paradigm started over 20 years ago and its application has increased exponentially with our knowledge of the disease. However, the current number of approved new cancer drugs that target the underlying molecular determinants of cancer are still relatively few in number. In the introduction to this year's session on rational cancer therapy, we'll review the status of some innovative therapeutic approaches that have been presented over the past several years at this Conference. These approaches include inhibitors of protein kinases (1, 3), cyclooxygenase-2 (4), angiogenesis (6), farnesyltransferase (5), and matrix metalloproteinases (2), among others. Additionally we'll examine the recent Oncologic Drugs Advisory Committee (ODAC) recommendations on cancer chemotherapeutics submitted for FDA marketing approval as an indicator of the uptake of innovative new agents that target the molecular pathophysiology of cancer.
Advances in Lung Cancer Therapy
PAUL A. BUNN, JR, University of Colorado Cancer Center Denver, Colorado 80262
Lung cancer is the leading cause of death in the United States and throughout the world, representing more than 28% of all cancer deaths in the United States. The 5-year survival rate remains less than 15% despite some gains in all forms of therapy including chemotherapy, radiation therapy, and surgery (4). The majority of patients present with advanced stage III and IV disease that is rarely cured by surgery alone. Even in the 25% of patients presenting with stage I or II disease, the majority are not cured by surgery alone due to recurrence in undetected metastatic sites. Newer chemotherapeutic agents introduced in the last decade have reduced the hazard rate of death by 32% or more in patients with advanced stage IV non-small-cell lung cancer (NSCLC) (1) . These agents, such as paclitaxel, docetaxel, vinorelbine and gemcitabine, were less toxic than previous agents and were shown to improve quality of life as well as survival (4) . Randomized trials showed that the combination of one of these new agents with cisplatin or carboplatin produced superior survival compared to cisplatin alone (19) . More recent randomized trials also showed that these 2-drug combinations (paclitaxel/carboplatin, gemcitabine/carboplatin, and docetaxel/cisplatin) provided superior survival compared to paclitaxel, gemcitabine, or docetaxel alone (14) . Randomized trials have shown equivalent efficacy of several 2-drug combinations but have not shown 3-drug combinations or alternating combinations to be superior to 2-drug combinations (2, 11) . Chemotherapy has also been proven to improve survival in elderly NSCLC patients with advanced disease and to improve survival in the second line setting after the failure of first-line chemotherapy (8, 18) .
In stage IIIB NSCLC, randomized trials demonstrated superior efficacy for the combined use of chemotherapy with radiotherapy compared to radiotherapy alone (7, 15) . Recent randomized trials showed superior results when the 2 modalities were administered concurrently rather than sequentially. Up to 20% of stage IIIB patients may survive 5 years with concurrent combined modality (5) .
For patients with unresectable stage IIIA, (usually due to the presence of mediastinal lymph node metastases, N2), treatment with chemotherapy and radiotherapy or chemotherapy followed by surgery is generally preferred over surgery alone and is associated with 5-year survival rates of about 20% (1, 17) . Completed randomized trials have evaluated whether triple modality therapy is superior to 2 modalities and the results of these trials are eagerly awaited.
Patients with stage I and II disease are treated with surgery alone. There is no evidence that pre-or postoperative radiotherapy improves survival though it may reduce local recurrences (3) . A meta-analysis of trials of postoperative chemotherapy showed that it reduced the hazard rate of death by 13% that was associated with a 5% higher 5-year survival rate (3) . However, the number of patients was small and the p-value was of borderline significance ( p = .08) (3) . There are theoretical reasons why preoperative chemotherapy could be superior to post-operative chemotherapy. Phase II studies and small randomized trials suggest that preoperative chemotherapy followed by surgery may be superior to surgery alone (6, 16) . Randomized trials addressing this issue are in progress.
Recent advances in the molecular understanding of and pathogenesis of lung cancer have led to clinical trials using agents targeted at the EGFR receptor, angiogenesis, farnesylation of ras, RXR receptors, PKC inhibitors, and others. Many of these agents have already completed phase I and Phase II studies. Promising results have been reported for several agents including small molecule receptor tyrosine kinase inhibitors (eg, ZD1839), angiogenesis inhibitors (anti-VEGF antibody), antisense PKC alpha inhibitors (ISIS3521), and RXR inhibitors (bexarotene) (9, 10, 12, 13) . ZD1839 was evaluated in 2 trials in which patients, who had failed 2 or more chemotherapy regimens (Ideal 2) (13) or 1 or more chemotherapy regimens (Ideal 1) were randomized to 1 of 2 oral doses of daily ZD1839 (250 mg vs 500 mg) (9) . Objective response rates of 12% to 19% were noted in these trials and symptomatic response rates exceeded 40% in both trials. A dose of 250 mg was as effective as a dose of 500 mg and produced less toxicity. The most common toxicity was skin rash that was not life threatening, that was always reversible and that usually improved even with continued therapy. ZD1839 was successfully combined with 2-drug chemotherapy combinations and randomized trials comparing chemotherapy alone to chemotherapy plus ZD1839 have been completed. The results are eagerly awaited. The results of randomized trials comparing chemotherapy alone to chemotherapy plus anti-VEGF, plus ISIS3521 and plus bexarotene are in progress or have been completed and results are also eagerly awaited. The fact that p53 mutations occur at high frequencies in human cancers and are associated with poor patient prognosis and drug resistance has prompted an enormous effort to determine what biological activities p53 uses to suppress tumor development. p53 was initially identified as the "guardian of the genome" based on its ability to mediate a G1 arrest following DNA damage. However, studies using approaches ranging from p53 overexpression to gene-targeting in mice have revealed that p53 can participate in many processes involved in maintaining cellular integrity following stress, including cell-cycle checkpoints, DNA repair, senescence, apoptosis, angiogenesis, and the surveillance of genomic integrity. The relative contribution of each of these processes to tumor suppression is not known. In principle, the simultaneous inactivation of all p53-associated activities could provide an enormous advantage to a developing or treated tumor cell that mutates p53; conversely, inactivation of a single p53 function might provide an essential new capability whereas the other defects may be by-products of p53 loss.
SPECIAL LECTURE
We hypothesized that complete ablation of crucial p53 effector functions may produce tumors that are phenotypically identical to those with p53 mutations yet retain wild-type p53. To this end, we examined the ability of dominant-acting genes that completely disable apoptosis downstream of p53 to phenocopy the effects of p53 mutations during tumor development and treatment responses in the Eµ-myc transgenic mouse. These mice overexpress the c-myc oncogene in the B-cell lineage and develop pre-B or B-cell lymphoma by several months of age (1) , and provide an ideal setting in which to study p53 function during tumor development. First, tumors arising in these animals closely resemble the genetics and pathobiology of human Non-Hodgkin's lymphoma (1) . Second, p53 acts as a potent tumor suppressor in this model, since spontaneous p53 mutations occur in a subset of Eµ-myc lymphomas (2, 5) . Third, experimental inactivation of p53 dramatically accelerates lymphoma onset and invasiveness and promotes drug resistance (5) . Finally, the system is experimentally tractable, because genes can be introduced into established lymphomas or premalignant hematopoietic stem cells ex vivo (6, 7) . This latter feature allows one to study the impact of specific genes on tumor behavior following transplantation into syngeneic recipients, and to tag tumor cells with fluorescent proteins for whole body imaging of tumor behavior in live mice.
Using this model, we show that disruption of apoptosis downstream of p53 by Bcl2 or a dominant-negative caspase 9 confers-such as p53 loss-a selective advantage, and completely alleviates pressure to inactivate p53 during lymphomagenesis. Despite their p53-null-like aggressive phenotype, apoptosisdefective lymphomas that retain intact p53 genes do not display the checkpoint defects and gross aneuploidy that are characteristic of p53 mutant tumors (3). Therefore, apoptosis is the only p53 function selected against during the lymphoma development, whereas defective cell-cycle checkpoints and aneuploidy are mere by-products of p53 loss. Nevertheless, genomic instability and other by-products of p53 loss-while not selected for initially-may confer additional capabilities to the tumor as it encounters new stresses or environments. Indeed, while Bcl2 overexpression produces lymphomas that are phenotypically identical to p53 mutant tumors, animals harboring Eµ-myc lymphomas overexpressing Bcl2 have a better prognosis following cancer therapy than those harboring tumors with mutant p53. This is because another by-product of p53 loss-defects in cellular senescence-supplies an additional capability to a tumor that is revealed only under therapy, and this capability is not conferred to Eµ-myc lymphomas overexpressing Bcl2. Hence, tumors expressing Bcl-2 but retaining wild-type p53 undergo a prolonged cell-cycle arrest that shows features of cellular senescence (4) .
Additional insights into drug action were obtained by studying the contribution of the INK4a/ARF locus to tumor development and therapy. Interestingly, we observed that the disruption of ARF accelerated lymphomagenesis whereas loss of INK4a had little effect; in contrast, disruption of INK4a was associated with a much poorer response to therapy than loss of ARF (4). This difference in treatment outcome appeared to arise from the inability of INK4a null cells to efficiently enter a senescence program following therapy. Consequently, the way in which the INK4a/ARF locus is mutated during tumor development produces heterogeneity in treatment responses. ARF mutations promote lymphomagenesis, whereas INK4a mutations (alone or in combination with ARF) have no additional impact. Nevertheless, owing to their proximity, ∼25% of Eµ-myc lymphomas acquire spontaneous mutations that disable both genes-here, INK4a loss is a byproduct of ARF mutations. This proximity also allows mutations targeting one gene (ARF) during tumor development to facilitate loss of the other gene (INK4a) under therapy. Hence, the precise way in which ARF is mutated during lymphomagenesis has a profound impact on treatment outcome-mice harboring tumors that have disrupted both genes have a worse prognosis than those with tumors lacking ARF alone.
The Eµ-myc model is remarkably simple. Each tumor analyzed was initiated by the same oncogene (myc), arose in the same strain (C57BL/6), and was treated with the same drug (CTX). Yet, these tumors displayed an extraordinary heterogeneity in treatment responses, ranging from cure to progression under therapy depending on their genotype. Given the complexities of human oncology, it is no wonder that treatment responses are remarkably variable and difficult to predict. Undoubtedly this inherent variability will remain a problem, even as we enter the age of targeted therapeutics. Still, our study provides a new paradigm to understand drug action and inherent variations in treatment sensitivity, and provides support for the view that tumor genotype is the most important determinant of treatment outcome. These principles, when applied to human tumors, provide a strong rationale for individualized cancer therapy based on knowledge of drug action and tumor genotype. Mitochondria undergo marked structural and functional alterations following a lethal cellular injury. These may be divided into those changes prior to cell death (prelethal phase) and those following cell death collectively termed necrosis. The 2 known prelethal phases, known as oncosis and apoptosis, play important roles in the pathogenesis and pathophysiology of cellular death. The relative importance and duration of each varies with the type of injury including etiologic agents, ATP concentration in the cell, and genes being expressed. Structural and functional changes include alterations in ATP synthesis; ion permeability and transport; the mitochondrial membrane potential; alteration of the mitochondrial transition pore; release of enzymes, pro-enzymes, and cofactors; release of inhibitors and promoters of cell death, eg, bcl-2, procaspases, SMAC/DIABLO, and cytochrome c; and generation of reactive oxygen-and nitrogen species.
PANEL DISCUSSION
Prelethal changes in both apoptosis and oncosis include loss of matrical granules, matrical condensation, and then matrical swelling with rupture of the outer membrane; in oncosis cellular ATP concentration approaches 0 very rapidly; this is not the case for apoptosis where ATP is required. In this phase the mitochondria later show swelling of the inner compartment-is probably corresponds to the mitochondrial permeability transition (mPT). Opening of the permeability pores is followed by mitochondrial swelling, membrane depolarizaion, and the release of Ca( 2+ ) and other solutes including cytochrome c. Release of cytochrome c from mitochondria appears to be an important mediator in many types of apoptosis; cytochrome c is an important member of the respiratory chain but is a lethal toxin when released into the cytosol.
The mitochondrial area is one that demands the development of interventions both for causing and preventing cell killing. One example is over expression of bcl-2, which is protective against killing by both apoptosis and oncosis. Another key area is the prevention of the mPT by developing drugs that inhibit the PT such as currently used cyclosporin A and trifluoperazine. Newly described proteins that appear to initiate oncosis are uncoupling factor 2 and porimin, a cell surface receptor.
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Mitochondrial Permeability Transition (MPT)
Inhibition of oxidative phosphorylation progresses to uncoupling when opening of cyclosporin A (CsA)-sensitive permeability transition (PT) pores increases permeability of the mitochondrial inner membrane to small solutes (reviewed in 3). Involvement of the MPT in necrotic and apoptotic cell death is implicated by demonstrations of protection by CsA against oxidative stress, ischemia/reperfusion, tumor necrosis factor-α (TNFα) exposure, Fas ligation, calcium overload, Reye-related drug toxicity, and excitotoxicity (2, 3). Confocal microscopy directly visualizes the MPT in single mitochondria within living cells from the translocation of impermeant fluorophores, such as calcein, across the inner membrane. Simultaneously, mitochondria release potential-indicating fluorophores. Subsequently mitochondria swell, causing outer membrane rupture and release of cytochrome c and other proapoptotic proteins from the intermembrane space.
Ischemia/Reperfusion Injury
During ischemia, tissue pH decreases rapidly by 1 unit or more, whereas tissue pH returns to normal after reperfusion. This naturally occurring acidosis of ischemia (pH ≤ 7.0) protects profoundly against the MPT and onset of necrotic cell death in hepatocytes, cardiac myocytes, and other cell types. However, the return from acidotic to normal pH after reperfusion precipitates cell killing, a pH paradox. Cytoprotection is directly linked to changes of intracellular pH rather than to pH-linked secondary changes of cytosolic Na + or Ca 2+ . In cultured hepatocytes and myocytes, pH-dependent reperfusion injury is associated with onset of the MPT, which does not occur until intracellular pH returns to 7 or greater.
Apoptosis vs Necrosis
In situ, a sequence of decreased mitochondrial NAD(P)H, increased mitochondrial free calcium and increased mitochondrial formation of reactive oxygen species promotes the MPT. Necrotic or apoptotic cell death after the MPT depends, in part, on ATP levels. If ATP levels fall profoundly, a glycine-sensitive anion channel in the plasma membrane subsequently opens, leading to colloid osmotic swelling, plasma membrane rupture and necrotic cell death (4) . If ATP levels are partially maintained, cytochrome c release after the MPT initiates ATP-dependent activation of caspase 9 and caspase 3, which then causes apoptosis. In death receptor activation (TNFα receptor, Fas), caspase-8 activation leads to Bid cleavage, translocation to mitochondria, onset of the MPT, and activation of the mitochondrial (Type 2) pathway to apoptosis. When the MPT is blocked or Bid is deficient from hepatocytes, a slower nonmitochondrial (Type 1) pathway to apoptosis is revealed that involves direct activation of caspase 3 by the Death-Inducing Signaling Complex (DISC).
Apoptosis
The MPT also signals mitochondrial autophagy, a process that may be important in removing damaged mitochondrial DNA (1). MPT-dependent autophagy occurs during hepatocellular remodeling with prolonged culture and after nutrient deprivation. CsA and its non-immunosuppressant analog, NIM 811, block mitochondrial autophagy, whereas tacrolimus, an immunosuprressant and calcineurin inhibitor that does not block the MPT, fails to inhibit mitochondrial autophagy.
Necrapoptosis
Cellular features of necrosis, apoptosis and autophagy frequently occur together after death signals and toxic stresses. A new term, necrapoptosis, describes such death processes that begin with a common stress or death signal, progress by shared pathways, but culminate in either cell lysis (necrosis) or programmed cellular resorption (apoptosis) depending on modifying factors such as ATP.
SESSION 6: EMERGING TECHNOLOGY IN PHARMACOLOGICAL RESEARCH AND DEVELOPMENT
From Genes to the Whole Animal: Bridges, Links, Switches, and Opportunities to Make Medicine TIMOTHY A. BERTRAM, Pfizer Inc, Eastern Point Road, Groton, Connecticut 06340
Emerging Pharmaceutical R&D approaches focus on gathering and analyzing complex biological data obtained from various molecular and integrated systems analyses. Acquiring this information early in the discovery and development process allows for preclinical measurements to be directly translated to clinical studies thereby providing a basis of defining risks and benefits of new therapeutic agents. Noninvasive imaging technologies allow longitudinal evaluation of living systems that can be compiled with molecular and biochemical analyses to bridge from the whole organism to molecular signaling pathways. Through bioinformatics, molecular analyses can be merged with phenotypic measurements (eg, imaging) to link seemingly unrelated biological events to give a holistic view of the living organism.
Imaging as an Hypothesis-Testing Approach
Various Nuclear Magnetic Resonance (NMR) technologies enable the acquisition of metabolic, anatomical and physiological information. NMR allows for noninvasive acquisition of biological information with out the use radiation. However, this technology lacks sensitivity, is sensitive to motion and, generates a high magnetic-field environment. When NMR is used to generate spectroscopic analysis, using paramagnetic elements such as 31 P (mitochondiral energetics), 1 H (evaluation of lipid metabolism), and 13 C-NMR (determine glycogen turnover), cellular metabolism can be assessed within the context of anatomical locations. Using 23 NA, ion-transport studies can be linked with images of cellular and tissue localization and 19 F-NMR can be used to study the in vivo metabolism of drugs (eg, 5 flurouracil). When these approaches are combined with imaging studies, powerful insights into disease processes and potential benefits or risks from therapeutic agents can be studied in a longitudinal fashion. The ability to switch between gene or protein expression patterns and phenotypic characterization allows for the identification of therapeutic agents that target specific cells or tissues that form the basis of a disease or toxicity condition.
Positron emission tomagraphy (PET) is a nuclear imaging technique that allows the assessment of spacial and temporal distributions of compounds labeled with a positron-emitting radionuclide. This technology permits the evaluation of metabolic pathways, gene expression patterns, or receptor profiles. New optically based technologies use fluorescent probes that allow the generation of projection images in vivo. A variety of PET tracers have been synthesized to study biological systems such as blood flow metabolism, receptive building, enzyme activity, gene expression, and drug localization. Gene specific radioactive antisense oligodeoxynucleotides (ie, RASONS) allow the evaluation of gene expression through imaging. Reporter gene approaches can be applied using transgenic animals and luciferase or green-fluorescent labeled proteins.
Ultrasound imaging uses sound waves to produce an image or if used in Doppler-mode to assess the movement of selected tissues (eg, blood). Advances in this technology now allow for anatomical characterization of internal organs in rats and mice. As with other imaging tools, contrast-enhanced imaging has improved the utility of this method. Ultrasound biomicroscopy can visualize tissues at microscopic levels with axial resolution ranging from 60 to 19 um and lateral resolution ranging from 250 to 60 um.
Bioinformatics as a Hypothesis Generating Approach
Bioinformatics (aka In silico Biology) is the use of computational approaches to model, predict, and explain biological functions. The growing size of databases filled with clues as to how life systems function are so large that they now require bioinformatics to sort through all the information. This tool allows for optimal utilization of sequence, expression, and structural information obtained from transcriptome and proteome profiling. Genomic DNA sequences can be exploited to identify potential targets for therapeutic intervention or biomarkers that can identify biochemical pathways and disease progression. Modes of gene regulation as well as susceptible genotypes can be predicted from single nucleotide polymorphism data. In silico approaches allow for the generation of new hypotheses and the design of appropriate experimental studies to interpret industrial-scale generation of biological information. Bioinformatics can help define the molecular targets that are differentially expressed in cells, tissues, or organs. This approach can also give insights into the presence or absense of detoxifying enzymes or presence of bioactivating proteins in potential target tissues. Knowledge of the distribution and abundance of these molecular targets can aid in the prediction of pharmacological or toxicological outcomes of potential new medicines. 
Whole Animal Imaging

Using PET to Monitor Somatic Gene Transfer
One of the major limitations in studying somatic gene transfer is the inability to monitor the location, magnitude and duration of gene expression following transfer of DNA, regardless of the DNA delivery system employed. Our goal has been to develop robust, reliable systems that permit investigators to monitor these parameters of gene expression following somatic transfer of DNA. To achieve this objective, we have used reporter genes whose protein products sequester positron-labeled reporter probes, and detected the reporter-gene dependent retention of the positron-labeled probes, in living animals, by positron emission tomography (PET). We developed 2 "PET reporter gene" (PRG) systems, 1 based on enzyme-dependent sequestration of a positron-labeled reaction product, the second based on receptor-dependent sequestration of a positron-labeled ligand.
The Herpes Simplex Virus Type 1 Thymidine Kinase Gene as a PET Reporter Gene
We have used the Herpes Virus Simplex Type I thymidine kinase (HSV1-TK) as a PRG and positron-labeled acycloguanosines as the PET reporter probe (PRP) (1) . Noninvasive, quantitative, and repetitive imaging of the HSV1-TK system has been demonstrated in both adenoviral transfer systems and in transgenic animals expressing the HSV1-TK in the liver from an albumin-TK transgene. We have created a "second generation" HSV1-TK PET reporter gene, that has a greater affinity for acycloguanosines and a reduced affinity for thymidine, increasing its efficacy as a PRG (2) . We have also identified a side-chain labeled form of penciclovir as the best PET reporter probe.
The Dopamine D2 Receptor as a PET Reporter Gene
We have also used the dopamine D2 receptor (D2R) and positron-labeled spiperone, a D2R antagonist, as a second PRG/PRP system and demonstrated the efficacy of this system, both in adenovirus mediated gene transfer and in tumor xenografts expressing the D2R gene (5) . Ectopic expression of the D2R might alter the physiology of target cells, reducing cAMP levels as a result of the interaction of endogenous ligands with the D2R. A second generation D2R PRG was developed that uncouples ligand-binding from activation of signaling pathways activated by D2R (3).
Bicistronic Vectors with PET Reporter Genes Can Accurately Reflect the Transfer of 2 Coding Units
Utilizing bicistronic vectors, both in stably transfected tumor cells (6) and in viral vectors (4), we have shown in vivo that PET measurement of a PRG placed distal to an internal ribosomal entry site (IRES) accurately reflects the expression of a second gene placed proximal to the IRES. As a result, it is possible to quantitatively reflect the expression of a "therapeutic gene" by assessing the expression of a reporter gene. TOXICOLOGIC PATHOLOGY
Spontaneous and Induced Mutants
Attempts at generating animal models for cancer included spontaneous or induced (radiation and chemical) ones as well as genetically induced mice. Examples of induced cancer models include the Apc/min mouse as an animal model of colon cancer. These models relatively closely model the human disease and have been very useful in identifying genes that cooperate in tumorigenesis and in therapeutic studies that explore the chemotherapeutic potential of drugs. Celecoxib (Celebrex) is a drug that is indicated for the treatment of familial adenomatous polyposis and much of the mechanistic/pharmacological studies for this drug were carried out in the Apc/min mouse. However, the number of spontaneous or induced-mutant mice as models of human disease that have been generated are relatively few.
Genetically Engineered Mice
Since the 1980s, transgenic and knockout mice have been generated and investigated for their utility as animal models for human cancers. Tumor models that use conventional transgenic or knockout mice have not in general been good models of sporadic human cancers, because the initiating mutation is present in all cells of a specific tissue or throughout the body. These cells include those that constitute the tumor microenvironment. To overcome this limitation, various methods for conditional tumor-suppressor gene mutation and oncogene activation in genetically engineered mice have been explored and these have met with greater success in generating mouse models of sporadic human cancers. Tumor growth and maintenance in mice with regulatable oncogene expression depends, in most cases, on continuous oncogene expression, supporting the validity of these factors as therapeutic targets.
The conventional knockout of tumor suppressor genes have also been limited in their success of generating mice that model human cancers largely because many of these tumor suppressor genes have developmental functions and the elimination of these genes in all cells during development report the earliest phenotypes; often embryonic lethality or developmental/morphological aberrations thus limiting their use in developing tumors which frequently necessitate the mice having to survive for substantial periods postnatally. Recombinasemediated conditional gene mutation can be used successfully to circumvent embryonic lethality or unwanted tumorigenesis in conventional tumor-suppressor gene knockouts.
Future Developments
Recent methodologies that are being explored are however showing great promise in facilitating the genesis of appropriate animal models for human cancers. Combining mouse models of sporadic cancer with various genome-wide screens for genetic alterations allows a comparison, on a molecular level, of mouse tumors with their human counterparts, and facilitates the discovery of new cancer genes and pathways that are involved in multistep tumorigenesis. Furthermore, mouse imaging systems that enable the noninvasive monitoring of tumor development will render conditional mouse models of sporadic cancer particularly useful for preclinical testing of therapeutic intervention or chemoprevention strategies. 
INTRODUCTION
The p53 tumor suppressor is structurally altered in about half of all human tumors and may be functionally impaired in up to 80% or more of all human cancers (3, 9) . It is activated by an array of cell stresses to induce one of several biological outcomes. These include cell cycle arrest, apoptosis, differentiation, and senescence, all of which are antiproliferative in nature and serve to protect the organism against the formation of a nascent cancer cell (3, 9) .
The association of p53 with senescence comes from a number of cell culture studies, including the induction of senescence in primary rodent cells by overexpression of activated Ras (2, 6) . This Ras induced senescence is p53-dependent and results in a terminal cell cycle arrest that resembles that observed in cells exhibiting replicative senescence. An obvious question is whether this p53-associated senescence correlates with any attributes of organismal aging. In fact, hints of such an association have arisen from several genetically engineered mouse lines that exhibit altered aging phenotypes. The telomerase knockout mice, Ku 80 knockout mice, p66Shc knockout mice, and XPD knockout mice all have altered aging phenotypes and longevity and may have alterations in p53 signaling (1, 4, 5, 8) . Recently, our laboratory has generated and characterized an apparent p53 hypermorphic mutant mouse that exhibits attributes of accelerated aging, more directly implicating p53 as an important agent in the aging process (7). This work is described below.
RESULTS
While attempting to engineer a mouse with a germ line p53 point mutation, we serendipitously produced a p53 deletion allele in ES cells that was missing p53 exons 1-6 while retaining exons 7-11. Mice with the p53 deletion (designated the "m" allele) were generated. The resulting p53+/m mice expressed a truncated p53 message encoding exons 7-11 in most of their tissues. Sequencing of the m allele mRNA revealed a fusion of exons 7-11 to a leader sequence of unknown origin that enabled initiation of translation from an in-frame methionine codon and would result in a C-terminal truncated p53 protein (a.a. 240-390). Examination of protein lysates from several mouse tissues with a p53-specific antibody revealed the presence of the expected 24-kD protein in the p53+/m lysates but not in the p53+/+ lysates.
p53+/m mice were highly resistant to spontaneous cancers. Less than 6% of p53+/m mice developed tumors, while >80% of p53+/− mice and >45% of p53+/+ mice of the same genetic background developed tumors. The p53+/m mice after 12-18 months of age exhibit appearance of early agingassociated phenotypes, including muscle atrophy, osteoporosis, loss of body weight, skin atrophy, and atrophy in a number of organ systems. These phenotypes are accompanied by reduced tolerance to a variety of stresses, including 5-FU myeloablation, wound healing, and general anesthetics. Mean and maximal longevity of p53+/m mice show significant decreases from p53+/+ controls.
The cancer resistance and early aging phenotypes of the p53+/m mice led us to hypothesize that the m allele product interacts with wild-type p53 to cause an increased p53 activity in these animals. Comparison of the p53 response to ionizing radiation in p53+/−, p53+/+, and p53+/m mice is consistent with this. Moreover, in vitro experiments with m allele expression constructs indicate that m can enhance wild-type p53 transactivation and growth suppression activities.
A second p53 transgenic model, generated by Alan Bernstein, and containing multiple copies of a temperature sensitive mutant allele of p53, also showed some of the early aging attributes seen in p53+/m mice. We believe that p53, in addition to its primary role of cancer prevention, may also affect aspects of aging, particularly through its influence on stem cell functional capacity.
To test whether p53 influences stem cell function, we initiated studies on several stem compartments in p53+/+, p53+/−, p53−/−, and p53+/m mice. Preliminary experiments indicate that p53+/− and p53−/− mesenchymal and hematopoietic stem cells and precursor cells have augmented proliferative potential compared to their wild-type counterparts. In addition, the p53+/m stem and precursor cells clearly show a decrease in proliferative activity that equals or is less than that of p53+/+ counterparts. This latter result is consistent with a model that a more precipitous decline in p53+/m stem cell function with age may be responsible for some of the early aging phenotypes in the p53+/m mice.
DISCUSSION
We believe that the 2 mutant p53 lines of mice discussed here implicate p53 in some aspects of organismal aging. This extends previous in vitro data linking p53 to cellular senescence. The early aging phenotypes observed in our 2 mutant lines may be a direct result of increased wild type p53 activity in some cells. This increase in p53 activity may gradually inhibit stem cell function over the life span of the affected animal to produce failures in tissue homeostasis in key organs in a process that remarkably resembles accelerated aging. Tissue homeostasis requires a finely honed balance between cell proliferation and cell death. Cells rapidly respond to changes in their environment that may perturb this balance, but the response to these stimuli must be reversible in order to control the magnitude and duration of these effects within the cell. Feedback loops are an evolutionarily conserved mechanism to accomplish this type of regulation. For example, signaling via kinases and their associated phosphorylation cascades is balanced by the action of phosphatases. For the stress-activated protein kinases (SAPKs), there are at least 4 families of phosphatases comprised of over a dozen distinct phosphatases that regulate the activity of JNK and the p38 MAPKs (5) . Similarly, second messengers and mediators of stress responses are often bifunctional. Molecules that participate in cellular stress responses include cGMP, reactive oxygen species (ROS), and nitric oxide (NO). NO for example, can trigger both cell survival and apoptosis (2) and ROS can trigger signals that activate caspases and promote apoptosis but can also function to inhibit apoptosis by direct oxidation of caspases at critical cysteine residues.
In maintaining an appropriate balance between proliferation and apoptosis, the mitochondria plays a key role in cellular stress responses and integration of pro-and anti-apoptotic signals. In the case of ROS, the mitochondria are both a primary source and principal target for free radicals (1). Respiration-linked oxygen stress can result in loss of genomic and structural integrity of the mitochondria, leading to diminished function and ATP production. Mitochondria also figure prominently in both NO-induced apoptosis triggered by release of cytochrome c and NO-induced survival mediated by suppression of cytochrome c via production of cGMP (2) . The appreciation of the crucial role of the mitochondria in these and other cellular process has generated several initiatives to characterize the mitochondrial proteome (4) and to identify novel proteins that act as effectors of apoptosis in the mitochondria, such as mtCLIC (mitochondrial chloride intracellular channel) (3).
An understanding of cellular stress and signal transduction is relevant to many aspects of cancer. Stress responses are integral to the process of aging and apoptosis, processes that act to constrain cell growth and from which cancer cells must escape. Oxidative stress also participates in the pathogenesis of cancer and is a mechanism of carcinogen-induced DNA damage, for example via redox cycling of quinones. Furthermore, cellular stress contributes significantly to the side effects of cancer therapy, and interventions that would reduce these adverse side effects could improve the quality of life and clinical outcome of cancer patients.
Nitric Oxide and Cellular Stress
TIMOTHY R. BILLIAR, Department of Surgery, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15213
Nitric oxide (NO) is produced by 1 of 3 NO synthases (NOS). The relatively small amounts of NO produced by constitutive NO synthases regulate such basic functions as vasodilatation and neurotransmission. The inducible NOS (iNOS) is expressed under stress and inflammatory conditions and can produce high quantities of NO in a sustained manner. The consequences of NO exposure on cells depends on a number of factors, including cell type, redox status, and quantity and duration of NO exposure. The effects range from cytoprotection at low to moderate levels of NO production to cytotoxicity. The cytotoxicity of NO may also be related to the formation of toxic reaction products such as peroxynitrite which is thought to form when NO interacts with superoxide. In susceptible cells the toxicity of NO can be due to direct interaction with mitochondrial targets. For example, NO can inactivate cytochrome c oxidase leading to mitochondrial dysfunction and peroxynitrite formation. This may lead to cytochrome c release activating apoptotic pathways. In other settings NO can result in DNA damage resulting in the accumulation of p53 inducing cell cycle arrest and possibly apoptosis. NO has also been shown to activate c-JunN-terminal kinase resulting in cell death.
In stark contrast to the capacity of NO to activate apoptotic pathways in some cell types, similar concentrations of NO are profoundly anti-apoptotic in other systems. We have worked extensively with hepatocytes to demonstrate that NO suppresses hepatocyte apoptosis through multiple mechanisms. Among these are the direct inhibition caspase activation and activity through redox-based modification of the cystiene at the active site of all caspase enzymes. This process of S-nitrosylation is efficient in hepatocytes and endothelial cells, and may be related to the chemistry of NO in these cell types. For example hepatocytes are known to contain high levels of nonheme iron. NO can form stable iron-nitrosyl complexes in hepatocytes, and these are efficient S-nitrosylating species. NO can also activate guanylyl cyclase resulting in the increases in cGMP in hepatocytes. In hepatocytes cGMP has anti-apoptotic functions. We have shown that cGMP can activate AKT and thereby influence apoptosis. More recently, we have shown that cGMP can suppress increases in the adapter protein FADD. This appears to be mediated through a PKA-dependent effect.
NO also protects through the induction of stress proteins in hepatocytes as well as other cell types. Moderate to high concentrations of NO induces HSP70 expression which then protects hepatocytes from cell death. NO also effectively upregulates hemeoxygenase-1 (HO1). We have recently shown that the product of HO1, carbon monoxide (CO), is also profoundly anti-apoptotic in liver cells. CO itself can upregulate iNOS in hepatocytes suggesting an important feedback loop. Ultimately understanding the roles of nitric oxide in cell survival, may lead to a better understanding of the role of NO in organ protection as well as abnormal apoptosis as seen in tumor formation. p53 exerts part of its biological functions as a tumor suppressor through the activation or repression of specific target genes via sequence-specific binding to promoter regions. p53 is frequently mutated and often subjected to loss of heterozygosity in both preneoplastic and malignant skin tumors as a consequence of the mutagenic action of ultraviolet light. Furthermore, loss of function or ablation of p53 in mouse epidermis enhances malignant progression of chemically induced skin tumors. Mouse skin tumors deficient in p53 function are generally poorly differentiated squamous cell carcinomas, and this suggested that p53 could be involved in the differentiation program of epidermal keratinocytes (3, 5) . In fact, p53 transcriptional activity increases in keratinocytes induced to differentiate in culture (4). During a search by differential display analysis of differentiating mouse keratinocytes from p53+/+ and p53−/− mice, a novel chloride intracellular channel (CLIC) gene, clone mc3s5 (now identified as mtCLIC or CLIC 4) was identified as being differentially expressed (1). The 4.2-kilobase pair cDNA contained an open reading frame of 762 base pairs encoding a 253-amino acid protein with 2 putative transmembrane domains. mtCLIC protein shares extensive homology with a seven member family of intracellular organelle chloride channels. mtCLIC/ CLIC 4 is the only family member known to be differentially regulated. mtCLIC mRNA is expressed to the greatest extent in vivo in heart, lung, liver, kidney, and skin, with reduced levels in some organs from p53−/− mice. mtCLIC mRNA and protein are higher in p53+/+ compared with p53−/− basal keratinocytes in culture, and both increase in differentiating keratinocytes independent of genotype. Overexpression of p53 in keratinocytes induces mtCLIC mRNA and protein. Exogenous human recombinant TNFα also upregulates mtCLIC RNA and protein in keratinocytes. Subcellular fractionation of keratinocytes and immunofluorence analyses indicate that both GFP-mtCLIC fusion proteins and the endogenous mtCLIC are localized to the cytoplasm and mitochondria. Similarly, mtCLIC co-elutes with the mitochondrial and cytoplasmic fractions of rat liver homogenates. Sucrose gradient-purified mitochondria from rat liver confirmed this mitochondrial localization. Immunogold electron micrographs of human keratinocytes indicate that mtCLIC/CLIC4 associates with the inner mitochondrial membrane.
Dual regulation of mtCLIC/CLIC4 by 2 stress-response pathways suggested that this chloride channel protein might contribute to the cellular response to cytotoxic stimuli (2) . Treating normal keratinocytes with the DNA-damaging agents etoposide and doxorubicin upregulates mtCLIC contemporaneous with the onset of p53-mediated apoptosis. Overexpression of p53 by adenoviral transduction upregulates mtCLIC and induces apoptosis in both human and mouse keratinocytes. Transient transfection of an mtCLIC expression plasmid reduces mitochondrial membrane potential, releases cytochrome c into the cytoplasm, activates caspases and induces apoptosis. In human osteosarcoma cells engineered to express Bax regulated by a tetracycline-inducible promoter, mtCLIC enhances Bax-induced apoptosis without a demonstrable physical association of the 2 proteins. In human osteosarcoma cells engineered to express p53 regulated by a tetracycline-inducible promoter, antisense mtCLIC prevents the increase of mtCLIC and reduces apoptosis induced by p53. In contrast, antisense mtCLIC does not prevent apoptosis in the Bax inducible system, suggesting the two proapoptotic proteins function through independent pathways. Thus, mtCLIC, like Bax, Noxa, p53AIP1 and PUMA, participates in a stress-induced death pathway converging on mitochondria.
To determine if p53 is directly involved in regulating mtCLIC expression levels, the human mtCLIC promoter has been cloned and sequenced. Three putative p53-binding sites have been localized within a 3.5-kb region of the human mtCLIC promoter and cloned into reporter vectors. In several different transfected cell types, reporter activity increased in response to p53 upregulation, indicating that the human mtCLIC promoter has functional p53 response elements. Additionally, cytoplasmic mtCLIC translocates to the nucleus in cells undergoing apoptosis through overexpression of p53 or in response to apoptosisinducing chemicals, suggesting that nuclear translocation may represent a universal mtCLIC-mediated apoptotic response. Moreover, mtCLIC translocates to the nucleus in terminally differentiating and senescing keratinocytes, further suggesting that it may be involved in a death pathway associated with cellular differentiation and senescence. Immunoprecipitation of lysates from osteosarcoma cells undergoing p53-induced apoptosis or immunostaining of differentiating keratinocytes indicates that mtCLIC associates with the Ran nuclear import complex. To further explore the significance of mtCLIC nuclear translocation during apoptosis, organelle-specific mtCLIC fusion proteins were constructed and apoptotic effects were measured by annexinV staining and FACS analysis. In preliminary experiments, the nucleus-targeted mtCLIC increased the rate of apoptosis when compared with ER-, mitochondria-, or cytoplasmic-targeted mtCLIC, indicating that upregulation of mtCLIC and its subsequent translocation to the nucleus appear to be important factors in cellular apoptotic signaling pathways.
Our studies have confirmed that mtCLIC is an intermediate in p53 induced apoptosis, but its function in the TNF ∀ pathway is just now under study. TNF ∀ may be pro-apoptotic through death receptor or mitochondrial pathways, but its activation of NF6B also elicits a counteracting anti-apoptotic response. In human osteosarcoma cells, TNF ∀ treatment increases mtCLIC protein levels about 2-fold and only marginally induces apoptosis. Infecting these cells with an adenovirus encoding the I6B∀ superrepressor together with exposure to TNF ∀ increased mtCLIC protein levels 6-10-fold, without altering levels of Bax, and induced apoptosis in 85% of the treated cells. Together these results suggest that NF6B suppresses mtCLIC expression, and elevation of mtCLIC may participate in the pro-apoptotic response to TNF ∀. Since mtCLIC is associated with multiple pro-apoptotic pathways, additional studies have been undertaken to determine if this gene or its protein product could be a component of a tumor suppressor pathway. Preliminary studies of matched normal and tumor tissue samples from human cDNA arrays suggest that expression of mtCLIC is frequently diminished in a subset of human cancers. Similar reductions were observed for mtCLIC protein in experimental skin tumors. However, understanding the mechanisms involved in loss of mtCLIC expression in tumors or the significance to tumor formation awaits the development of in vivo models and genomic approaches. But could this technology be brought to bear directly on the study of human growth, development, and disease? The first major step towards this objective came in 1998, when Thomson et al reported the isolation and propagation of human embryonic stem cells from blastocysts that had resulted from in vitro fertilization (4) . The implementation of this technology promised numerous advances: greater insight into early embryogenesis, tissue differentiation, infertility, pregnancy loss, and birth defects; in vitro systems for screening candidate new therapies and assessment of toxicities; and a "regenerative medicine," in which the differentiated products of stem cells could be used in transplantation to treat a host of chronic degenerative diseases and disabling injuries. Perhaps the most visionary application of stem cells is the procedure known variously as "therapeutic cloning," nuclear transplantation, somatic nuclear transfer, and other terms. The intention of this strategy is to produce embryonic stem cells that are complete genetic matches with potential transplantation recipients. The feasibility of this approach can only be determined by much further study.
Despite its great and varied promise, stem cell research has fallen prey to deep ethical and political controversy. The genesis of this controversy is the fact that in the usual experimental protocol, blastocysts must be sacrificed in order to derive stem cells. For many among the US public, the sacrifice of blastocysts, even those destined for discard in fertility clinics or those produced without benefit of fertilization, is ethically unacceptable. Some hope has arisen that the dedicated stem cells found in adult tissues might possess the ability to "transdifferentiate" into a variety of tissues in response to a new tissue milieu or manipulations in vitro. At the moment, however, the prospects for this remain highly uncertain (5). The current political climate has greatly constrained research on human embryonic stem cells. Progress is likely to be slow until that climate has changed substantially.
Hematopoietic Stem Cells from ES Cells: Laying the Foundation for Future
Cell Therapies GEORGE Q. DALEY, Whitehead Institute and Harvard Medical School,
Human ES cells are a potentially unlimited resource for cell replacement therapies in malignant and degenerative disease. However, before clinical therapies are considered, an enormous amount of work remains to define differentiation programs that allow production of specific cell types. Our laboratory studies hematopoietic development during differentiation of embryonic stem cells in vitro. Our studies confront a fascinating and fundamental issue in developmental hematopoiesis-the distinctions between embryonic and adult hematopoietic stem cells-and are aimed at laying the foundation for producing hematopoietic transplantation therapies from ES cells for a host of bone marrow diseases.
The classical view of hematopoietic development holds that hematopoietic stem cells arise in the yolk sac and later migrate and assume residence in the bone marrow, where they generate blood throughout adult life. However, recent evidence suggests that yolk sac progenitors are largely restricted in their differentiation to primitive erythroid and myeloid lineages, and that the pluripotent hematopoietic stem cell responsible for lifelong lymphoid-myeloid hematopoiesis in the adult arises at a later stage within the embryo itself. Blood development from ES cells most closely mimics yolk sac hematopoiesis, and until recently, it was unclear whether methods for in vitro differentiation of ES cells generated adult-type, lymphoid-myeloid hematopoietic stem cells.
To address this issue, we exploited the capacity of the Chronic Myeloid Leukemia (CML)-associated oncoprotein BCR/ABL to promote proliferation of hematopoietic stem cells without blocking their differentiation. We transduced a BCR/ABL retrovirus into differentiating ES cells, isolated individual hematopoietic progenitors, and expanded the clones briefly in liquid culture. When dispersed in semisolid media, these cells spawned a large number of colonies consisting of primitive hematopoietic blasts, and a low frequency of primitive erythroid colonies containing yolk sac-type erythrocytes (verified by their expression of embryonic forms of hemoglobin). This suggested that BCR/ABL expression allowed us to culture a yolk sac type hematopoietic progenitor. When transplanted into irradiated mice, the cultured cells engrafted successfully in the bone marrow and generated terminally differentiated lymphoid, myeloid, and adult type erythrocytes in the circulating blood. Thus, in these experiments we identified a novel class of embryonic hematopoietic stem cells-a common progenitor for yolk sac and adult-type hematopoietic stem cells (2, 3). We are currently seeking to culture this cell from early mouse embryos to determine precisely when and where in development this cell appears.
Because animals engrafted with BCR/ABL-transduced ES cells succumb to leukemia, we were unable to test whether this novel class of embryonic hematopoietic stem cell could contribute to long-term blood formation, as expected for true hematopoietic stem cells. So our next challenge was to engraft normal hematopoiesis from differentiating ES cells. Toward this end, we attempted to stimulate the ES-derived embryonic hematopoietic stem cells with non-oncogenic proteins linked to BCR/ABL/cytokine receptor signaling (eg, an activated mutant of STAT5; a conditionally regulated form of the cytokine receptor c-mpl). While activation of STAT5 and c-mpl enabled us to propagate primitive hematopoietic populations from ES cells, none of the cultured cells generated more than transient engraftment in irradiated mice. We also tested HoxB4, because this homeobox gene has several properties that suggested it might endow adult engraftment potential on embryonic hematopoietic stem cells. HoxB4 is not normally expressed in yolk sac but becomes activated in adult hematopoietic stem cells, and overexpression had been shown to promote hematopoietic engraftment of bone marrow stem cells without leukemia. However, the hypothesis that HoxB4 might mature embryonic progenitors into adult-type hematopoietic stem cells had never been tested. Therefore, using inducible HoxB4, we activated expression during ES cell differentiation, and cultured primitive hematopoietic progenitors that resembled those stimulated by BCR/ABL. Importantly however, following transplant into mice, the HoxB4-modified cells generated long-term, multilineage hematopoiesis without evidence of leukemia. Moreover, the cells could be transplanted into secondary animals where they contributed to lymphoid and myeloid lineages over at least 6 months, therefore fulfilling the functional definition of the pluripotent hematopoietic stem cell (1).
Our observation with HoxB4 modification thereby established a means of using ES derivatives in therapeutic models of blood cell transplantation. In collaboration with Professor Rudolf Jaenisch, we employed this strategy in a mouse model of therapeutic cloning (nuclear transfer cloning combined with gene correction and cell therapy). We used nuclear transfer cloning from tail-tip cells of an immunodeficient Rag2−/− mouse to generate a Rag2−/− ES cell line, and repaired one allele by homologous recombination. We then differentiated the repaired Rag2+/− ntES line in vitro, transduced with HoxB4, and engrafted immunodeficient mice. The recipient mice showed partial reconstitution of B and T cell populations, Ig and TcR gene rearrangement, and IgM, IgG, and IgA in peripheral blood, thereby establishing that nuclear reprogramming and combined gene and cell therapy could be reduced to practice (4) . To generalize the potential applications of this methodology to other hematopoietic disorders, we are currently planning to test functional repair of other blood lineages in mouse models of white cell and red cell pathology (eg, neutrophil and platelet deficiency, sickle cell anemia, and thalassemia).
These studies represent a significant advance in our capacity to model hematopoietic stem cell development in vitro from ES cells, and to exploit ES cells to model therapeutic transplantation. In the long run, we hope to extend our analysis to human ES cells, and to establish culture conditions for generating human hematopoietic stem cells. Such cells can be tested for engraftment in immunodeficient mice (eg, NOD/Scid), which sustain multilineage human hematopoiesis and are FDA-accepted surrogates for testing hematopoietic transplant therapies prior to human clinical trials. One possible long-term goal is to combine nuclear transfer, ES cell generation, gene correction, and hematopoietic stem cell differentiation in the treatment of a patient with an amenable genetic or malignant disease of the bone marrow, like thalassemia, sickle cell anemia, or leukemia. The development of chemotherapeutic agents for the treatment of serious or immanently life-threatening disease presents unique challenges to researchers and regulators alike. Initiation of dosing and dose-escalation in clinical testing of oncology agents is frequently based on limited nonclinical and clinical data. Furthermore, initial marketing of oncology therapeutics is sometimes predicated on accelerated approval criteria (1), which may further limit the available safety and efficacy database in early clinical use, and thus necessitate additional postmarketing clinical and/or nonclinical testing.
Nonclinical testing paradigms have been developed to support the selection of a safe starting dose, early dose escalation, and chronic use procedures in the clinical testing of new molecular entities for the treatment of cancer. These paradigms are thought to effectively address safety concerns related to the development of cytotoxic agents (including photosensitizers and targeted drug delivery products), drugs to alter the efficacy of primary chemotherapeutics (ie, radiation and chemosensitizers), and drugs to be used chronically [chemopreventive and adjuvant (ie, hormonal agents and immunomodulators) drugs; (2)]. Recently, questions have arisen as to whether there should be a different approach to the safety assessment of new 'targeted' therapeutics.
Does the development of molecularly targeted therapies necessitate a paradigm shift in the non-clinical and/or clinical safety assessment of these drugs? It has been suggested that prior to clinical testing an extensive understanding of the agent's mechanism of action (MOA) is critical, along with the potential impact which modulation of the target (tumor and nontumor-related) may have, and the effects of sub-and suprapharmacologic doses on system response be well defined. To examine the limited experiences with targeted therapeutics, subsequent speakers will present several case examples from targeted therapies that have obtained marketing approval or are still undergoing premarket clinical and nonclinical assessment.
Is there or should there be a different approach to safety assessment in the development of new therapies beyond the realm of classic cytotoxics? Does the development of molecularly targeted therapies necessitate a paradigm shift in the approach to safety assessment of these new drugs? To evaluate what we have learned thus far we can examine targeted therapies that have obtained marketing approval. The development of imatinib mesylate demonstrates issues that distinguish these new therapies in terms of obtaining adequate preclinical data to support their transition into humans and planning their safety evaluation in clinical trials. Dose-finding and appropriate administration schedule should be considered. The understanding of the agent's mechanism of antitumor effect should be critically evaluated, and the potential general impact that target modulation could have on the patient, beyond its impact on the tumor itself, must be considered. The preclinical and clinical development of imatinib mesylate will be reviewed to see if, in retrospect, safety issues were predictable. Safety issues encountered in the development of trastuzumab and agents developed to target EGFR will be briefly discussed. Acetylation of histones is a major regulator of gene expression that acts by altering accessibility of transcription factors to DNA through modification of chromatin structure. In normal cells the balance between histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities helps to ensure cell specific patterns of gene expression. Perturbation of the balance produces changes in gene expression that can contribute to malignant transformation of cells.
Histone Acetylase Inhibitors as Potential Anticancer Agents
The hypothesis that chromatin modifiers will produce anti-tumor activity is supported by several observations: 1) Silencing of tumor suppressor genes at the level of chromatin is common in human tumors, 2) HDAC inhibitors have significant antiproliferative effects, such as promoting differentiation, cell cycle arrest or apoptosis, in tumor cell-specific manner, and 3) Induction of the cyclindependent kinase inhibitor p21 is observed when tumor cells are treated with HDAC inhibitors. p21 is a key mediator of G1 arrest and differentiation and this may be 1 mechanism by which HDAIs arrest cell proliferation and produce antitumor effects (reviewed by Marls et al, 2001).
Functional consequences of inhibiting HDA.
As HDAC inhibitors modulate gene expression they are also likely to interfere with normal cellular physiology leading to untoward effects. Summarized below are results of our efforts to develop HDAC inhibitors as efficacious and well tolerated anti-tumor agents.
HDA Enzyme Inhibition, Transcriptional Activation, and Antiproliferative Activity of NVP-LAQ824-CU
Through iterative design and combinatorial chemistry, the cinnamic acid derivative NVP-LAQ824 was synthesized as an HDAC inhibitor. LAQ824 inhibited a partially purified cellular histone deacetylase activity in low nanomolar concentrations (IC 50 = 0.03 µM), activated a p21 promoter luciferase construct transfected into H1299 cells and induced cell death in a time and dose dependent manner in a variety of tumor cell lines. However, the compound produced only a reversible cell cycle arrest in the normal diploid fibroblasts. Additionally, cell cycle analysis revealed that both tumor and normal cells accumulate in the G2/M phase of the cell cycle after LAQ824 treatment, but a subG1 population subsequently develops in tumor cell lines. Analysis of histones in LAQ824 treated cells revealed elevated levels of histone acetylation.
Effect of NVP-LAQ824-CU on Hematological Malignancies
Because tumor cells from leukemia patients are relatively accessible and the weak HDAC inhibitor sodium phenylbutyrate was reported to be effective in the treatment of a patient with acute promyelocytic leukemia (2), LAQ824 was tested against hematologic tumor cell lines and patient-derived primary leukemia cells. The compound induced marked growth-inhibitory and cytotoxic effects on 7 human or mouse liquid tumor (leukemia, lymphoma, myeloma) cell lines. More than 90% cell death of all the cell lines was observed was following 48 hours of incubation with the compound, irrespective of tumor origin. Annexin and propidium iodide staining of cells after 24 hours treatment with compound followed by FACS analysis indicated an apoptotic mechanism of cell death in all cell lines. An analysis of the effects of LAQ824 on primary leukemia cells freshly collected from patients with AML showed that low nanomolar concentration of LAQ824 was sufficient to induce cell death following 46 h of incubation with cells from two AML patients.
In Vivo Pharmacology and Toxicology
Evaluation of the antitumor activity of LAQ824 in human tumor xenografts implanted subcutaneously in athymic mice revealed dose-dependent inhibition of the growth of HCT116 human colon, A549 human lung, and MDA-MB435 human breast tumors. Furthermore, analysis of histone H3 and H4 acetylation levels in drug treated tumor xenografts from showed induction of histone acetylation by antiproliferative concentrations of the compound. These results support histone deacetylase inhibition as the mechanism of antitumor activity of LAQ824.
Although weight changes and side effects of LAQ824 treated athymic mice were minimal, administration of another HDAC inhibitor (LAL902) of similar structure as LAQ824 produced transient graying of the skin and eyes, lethargy, tremors, and breathing difficulties. Although LAQ824 did not produce these visible effects at efficacious doses, preclinical safety experiments that assess the effect of the compound on normal cardiovascular function were performed in rats and dogs. Overall, these assessments indicate that LAQ824 is a relatively safe antitumor drug candidate which is currently in phase 1 clinical trials. Dendritic cells (DC) are antigen-presenting cells that initiate immune responses by priming naïve T cells. Immature DCs efficiently capture antigen using several pathways such as macropinocytosis, receptor-mediated endocytosis via C-type lectin and Fcγ receptors, and phagocytosis of apoptotic and necrotic cell fragments (1, 2). After internalization antigens are processed via 2 major pathways to peptides that are incorporated in HLA class I and class II molecules. In the classical Class I pathway, endogenous proteins are processed in the cytosol, degraded by proteosomes to peptides, then transported across the endoplasmic reticulum by TAP dependent and independent mechanisms where they are complexed with MHC class I molecules. These complexes are transported to the cell surface where they are recognized by cognate receptors on CD8+ T cells. MHC class II molecules present peptides acquired from exogenous sources (soluble and particulate). After uptake by immature DC, the materials are then targeted to MHC II compartments where peptides are generated. The MHC II-peptide complexes are expressed on the DC surface available for recognition by CD4+ T cells (2) .
YOUNG INVESTIGATORS' ABSTRACTS
DCs also have the unique capacity to acquire antigenic materials from their environment and process these through the MHC class I pathway (crosspresentation) (2, 4) . Through this mechanism DCs process apoptotic cells, exosomes, heat shock proteins, proteins (soluble, particulate or antigen antibody complexes), and antigens encoded by RNA or DNA (4). Recently, Janjic et al, demonstrated that immature dendritic cells are capable of killing human solid tumor-derived cell lines as well as same explanted solid tumor cells but not normal cells (3) .
In this study we show that in vitro generated human monocyte-derived immature DCs are capable of inducing apoptosis in hematopoietic malignancies. DCs were isolated from peripheral blood from normal donors by the loosely adherent method. After 5 days of incubation with GM-CSF and IL-4, immature DC (confirmed by cell surface markers) were harvested and used as effector cells in the cytotoxicity assays. Targets consisted of 5 different hematopoietic cell lines (B and T cell lines) and whole blood from patients diagnosed with AML, CML, and ALL. Target cells and effectors were incubated for 3 hours in 3 E:T ratios: 1:10; 1:1 and 3, or 5:1. To measure immature DC induced cytotoxicity, we used a nonradioactive, cytotoxicity assay based on cell-permeable fluorogenic caspase substrates (5) In vitro generated immature DC induced apoptosis in the hematopoietic cell lines and AML, ALL, and CML cells in patients‚ peripheral blood, but not in normal PBLs. In all cases the percentage of dead target cells increased with the increasing the ratio in favor of effector cells.
In conclusion, our data show that immature DCs are capable of inducing apoptosis in hematopoietic malignancies. Thus, immature DCs can be important vectors in anticancer immunotherapy, not only by priming naïve T cells to recognize cancer specific antigen, but also by direct killing the tumor cells. The arginine methyltransferases CARM1 and PRMT1 associate with the p160 family of nuclear hormone receptor coactivators (3). This association enhances transcriptional activation by nuclear receptors. We describe a method for identifying arginine N -methyltransferase substrates using arrayed high-density protein membranes to perform solid-phase supported enzyme reactions in the presence of the methyl donor S-adenosyl-L-methionine. Using this screen, we identified distinct substrates for CARM1 and PRMT1. All PRMT1 substrates harbor the expected GGRGG methylation motif (5, 6) , whereas the peptide sequence comparisons of the CARM1 substrates revealed no such motif. The predominant CARM1 substrate identified in this screen was PABP1. Here we have mapped the methylated region of this RNA binding molecule in vitro and demonstrate that PABP1 is indeed methylated in vivo. Prior to these finding, the only known substrate for CARM1 was histone H3. Here we broaden the number of CARM1 targets, and suggest a role for CARM1 in regulating transcription/translation.
PABP1 Identified as an
Designing a Screen to Identify Novel Arginine Methyltransferases Substrates
In the quest for kinase substrates, successful screens have been employed using phage expression libraries. We reasoned that a similar approach could be used for the identification of PRMT substrates. All of the arginine methyltransferase enzymes, with the exception of PRMT2, are active as GST fusion proteins (1, 4) . This allowed the isolation of sufficient quantities of active enzyme to perform large-scale enzyme reactions on a solid support. We used arrayed protein library (2) induced on a PVDF membrane and then incubated with recombinant PRMT in the presence of 3 H-labeled S-adenosyl-L-methionine ([ 3 H]AdoMet), the universal methyl group donor. The high-density protein expression filters used in these experiments represent a novel product for high-throughput proteomics and were generated by the German Human Genome Project (DHGP). This human brain protein library contains 37,200 clones of His-tagged fusion protein arrayed and spotted in a duplicate pattern on 2 PVDF membranes. This approach has successfully identified substrates for 2 arginine methyltransferases, PRMT1 and CARM1 ( Figure 1A) . It was immediately obvious, when comparing the methylation patterns, that these 2 enzymes exhibit mutually exclusive substrate specificity. Identified substrates were obtained as bacterial stocks from the DHGP in Germany and retested to confirm that they harbored the expected Histagged fusion proteins and that the appropriate enzyme specifically methylated the recombinant protein substrates ( Figure 1B) .
The Identity of the PRMT Substrates
To determine the identity of the methylated fusion proteins, we isolated the expression vectors and sequenced the plasmid DNA. Five different proteins (hn-RNPU, CIRP, ILF3, FUS, RNA helicase A) were identified as PRMT1 substrates. Two of these proteins (hnRNPU and ILF3) have previously been described as harboring methylated arginine residues, thus providing proof that this in vitro screen can indeed identify proteins that are arginine methylated in vivo. All substrates are RNA binding proteins and they also contain RGG repeats which represent the methylation consensus sequence for known PRMT1 substrates (1, 5) . CARM1 methylates fewer recombinant proteins on the high-density protein expression filters than PRMT1, thus displaying greater substrate specificity than PRMT1 ( Figure 1A ). Here we have identified 2 new substrates for CARM1, the Poly(A)-Binding Protein 1 (PABP1) and TARPP. Neither of the CARM1 substrates harbor RGG motifs.
PABP1 is Methylated In Vivo by CARM1
We have disrupted the CARM1 locus in mice and generated MEFs from knockout and wild-type embryos. To determine whether PABP1 is methylated in these cell lines, we used the in vivo methylation assay. MEFs that are deficient in CARM1 (#20) are unable to methylate PABP1, whereas in the wild-type cell line (#13) PABP1 is methylated (Figure 2 ). This demonstrates that this in vitro screen has identified a genuine in vivo substrate. Moreover, there is no redundancy for CARM1-like activity-no other enzyme can cover for CARM1. Using GST fusions of PABP1 and site directed mutational analysis, we have identified the region in PABP1 that is methylated by CARM1. This 100 amino acid patch contains a propensity of proline and arginine residues. Moreover, thefactor p53 has long been recognized as "the guardian of the genome" for controlling cell cycle arrest and apoptosis in response to genotoxic stress (6) . Currently, much of the attention towards p53 is focused on deciphering the multiple and overlapping pathways resulting in posttranslational modification of the protein as it relates to transactivation. Our focus is directed at the function of p53 outside of transactivation, as a direct surveillant of genome integrity. Utilizing a combination of biochemistry and electron microscopy, we have identified several novel functions of p53; specifically that p53 binds directly to insertion/deletion lesions (IDL), mismatched DNA, Holliday junctions, and telomeric "t-loop" structures.
On a linear 25-base pair (bp) and 1.1-kilobase pair (kb) template we observed p53 binding with high specific affinity to a lesion consisting of three, 3-cytosine bulges (7) . p53 also bound A/G, C/C and C/T mismatches on a 49-bp template with an affinity similar to, or greater than, the human mismatch binding protein hMSH2-hMSH6 (3). In conjunction with other studies establishing p53 binding of DNA damaged by ionizing irradiation (10) and single strand DNA (1), these observations indicate that p53 can function as a direct cellular sensor of genomic damage.
Homologous recombination occurs naturally or during repair of damaged DNA. Holliday junctions are 4-stranded DNA functional intermediates in homologous recombination and must be resolved before anaphase otherwise the attached chromosomes will be broken during chromatid separation resulting in genetically aberrant daughter cells. Multiple groups have shown a loss of functional p53 correlating with increased amounts of homologous recombination (2, 9). Our efforts indicate that purified p53 binds a synthetic Holliday junction with very specific and high affinity in vitro (8) . Electron microscopic observation indicated that under conditions where p53 bound 50-60% of the Holliday junctions, 80-96% of the p53 molecules were located specifically at the junction (8) . In addition, p53 enhances the resolution of Holliday junctions by T4 endonuclease VII and T7 endonuclease I, suggesting a specific role for p53 in both the recognition and resolution of such structures (8) .
Human telomeric DNA is a hexameric (TTAGGG) repeat of approximately 10 kb at both ends of each chromosome and terminates in a 3 overhang of 100-200 nt. Our work has shown the 3 -overhang may invade the preceding duplex telomeric duplex DNA to form a "t-loop" protecting the chromosome end (4). Using a synthetic model telomere we have shown that p53 binds specifically to the 3-strand t-loop junction in vitro (11) . Under these conditions, p53 increases the formation of t-loops catalyzed by the telomeric repeat binding factor-2 (TRF2) by 2-fold (11). It is therefore likely that p53 plays a specific functional role at chromosome ends in the maintenance of t-loops through a stabilization of the t-loop or recruitment of TRF2 to assist in junction formation.
Our current focus is on the cellular interactions that may affect p53 surveillance of genome integrity. Recently we have observed modification of p53 Holliday junction and lesion binding activity by hMSH2-hMSH6 and the nonhistone chromatin protein HMG I(Y) (12) . In gel-retardation assays HMG I(Y) rapidly dissociates p53 from its specific interaction with Holliday junctions but does not affect p53 binding to bulged bases, whereas hMSH2-hMSH6 enhanced p53 binding to both the bulged bases and Holliday junction templates (12) . These data indicate there are protein interactions that can affect p53 binding to damaged DNA and hint to functional interactions within the cell. We are also currently investigating the effect of posttranslational modifications on p53 binding to DNA damage and Holliday junctions. Additionally, models to determine the affect of other proteins involved in genome maintenance, such as DNA dependent protein kinase (DNA-PK) and the Rad9-Rad1-Hus1 sliding clamp, on p53 interactions with DNA damage are being developed.
The current model of carcinogenesis is of an accumulation of several mutations leading to molecular and chromosomal alterations and eventual malignancy. Our data suggest that p53 functions at both the molecular and chromosomal level to monitor genomic integrity. Small lesions at the molecular level, IDLs and mismatched DNA, lead to mutations in daughter cells after replication. Functional intermediates such as Holliday junctions must be resolved and chromosome ends protected to avoid chromosomal damage. Therefore, the functional loss of p53 may have a 2-fold effect in cancer development. First, p53-mediated cell cycle arrest and apoptosis is lost inhibiting cellular capability to repair or eliminate cells with genomic damage. Second, the genomic surveillance capability of p53 is no longer present and cells may be more likely to develop both molecular and chromosomal damage. What remains to be deciphered is the cellular effects of p53 interaction with DNA lesions and implications to carcinogenesis. It is unknown if p53 binding to damaged sites is a primary step in the signaling of DNA damage and p53 directed cell cycle arrest or apoptosis. Also possible is that p53 binds damaged DNA or Holliday junctions after the initial signaling for repair or resolution to be in proximity of kinases such as ATM and DNA-PK that specifically modify the p53 protein (reviewed in 5). Last, p53 may be taking part in the repair and maintenance processes themselves through stabilization or recruitment of other factors. This is especially evident in p53 interactions with the t-loop structure of telomeres where p53 may play a role in maintaining chromosome structure independent of its transactivational capabilities. Chronic inflammation has long been recognized as a risk factor for the development of a variety of human cancers (2, 4) . Although the inflammatory mediators linking chronic inflammation to carcinogenesis are numerous, current information strongly suggests that nitric oxide (NO · ) contributes to this process (3). Unregulated production of this ubiquitous and physiologically important molecule leads to high levels of derivative reactive nitrogen species (RNS) that may be involved in pathological processes such as cancer. In particular, macrophages activated as part of the inflammatory process produce large quantities of both NO · and, by reaction with superoxide, peroxynitrite (ONOO − ). These 2 genotoxins have been shown to cause a wide variety of DNA lesions (1, 5, 6) . In addition to DNA cross-links, NO · -derived N 2 O 3 causes nitrosative deamination of G to produce xanthine and oxanosine; of C to produce uracil; and of A to yield hypoxanthine, uracil. ONOO − and its carbon dioxide derivative nitrosoperoxycarbonate produce oxidative base lesions including 8-oxoG, cyanuric acid, oxazolone, nitroimidazole and oxaluric acid. However, there is little known about the relative quantities of the different damage products arising under biologically relevant conditions, such as in activated macrophages. To this end, we have initiated a series of studies to define the predominant DNA damage produced by reactive nitrogen species, with a focus here on base deamination products.
Defining the
Our studies of N 2 O 3 -induced base deamination fall along 2-lines. The first goal is to define the spectrum of deamination products and cross-links that form in vitro and in vivo. To this end, we have developed a sensitive LC-MS approach to quantifying deoxyxanthosine, deoxyinosine, deoxyoxanosine, and deoxyuridine. We have synthesized isotopically-labeled internal standards for the 4 lesions and have achieved 1 picomole sensitivity at this point. The levels of these 4 deamination products have been determined in purified DNA exposed to NO in a recently developed NO delivery system that mimics the rate and intensity of NO production in inflammatory conditions. These studies will be extended to similarly exposed human TK6 cells and then to TK6 cells cocultured with activated macrophages. We have also shown that, contrary to popular opinion, deoxyxanthosine is a relative stable lesion with a half-life of 2.4 years in doublestranded DNA at pH 7.4 and 37 • C.
The second goal is to differentially map the location and quantity of base deamination products in human genes. To this end, we have adapted the technique of ligation-mediated PCR to map the lesions in the HPRT and p53 genes. A critical feature of these studies is the development of enzymatic tools to convert the base deamination lesions to strand breaks for LMPCR mapping. We have discovered 2 sets of DNA glycosylases that differentially recognize N 2 O 3 -and ONOO − -induced DNA lesions. Our results indicate that a combination of E. coli alkA and uracil glycosylase react selectively with DNA exposed to NO · , yet E. coli Fpg reacts selectively with DNA treated with nitrosoperoxycarbonate. There is little cross-reaction between the enzymes and lesion sets. The selected glycosylases were used to cleave DNA at sites of base damage in preparation for mapping of DNA lesions in the HPRT gene at single nucleotide resolution by LMPCR. As expected, our mapping results from the ONOO − -treated HPRT gene showed the damage pattern is by no means randomly distributed and that the lesions are concentrated on deoxyguanosine. We are currently analyzing the damage spectra produced by NO · exposure in this gene, with the goal of comparing the damage and mutational spectra (7) associated with these 2 mediators of inflammation. AuroraA (AurA), a ser/thr kinase, is thought to play a key role in the control of various mitotic events in proliferating cells. The transcription of AurA mRNA varies throughout the cell cycle and peaks during G2/M. The protein is localized to the centrosome, first detected in late G1/S-phase in the proximity of centrosomes, persisting until the completion of mitosis. It has been speculated that ectopic expression of AurA causes an increase in centrosome numbers, leading to aneuploidy and genomic instability, implicating AurA in tumor formation and development (1, 7) .
Overexpression of AuroraA Is an Early Event in Mammary Carcinogenesis
Centrosome abnormalities are associated with chromosomal instability and defects in cell polarity in tumor cells (2, 3) . For example, human adenocarcinoma cells display a number of abnormalities, including an increase in centrosome number and volume, accumulation of excess pericentriolar matrix, extra centrioles, and aberrant phosphorylation of centrosome-associated proteins, that are believed to contribute to genetic instability and cancer (4) (5) (6) .
In a study on tumorigenesis in rat mammary glands, we found AurA involved in centrosome amplification correlating with mammary tumor formation. A well-established carcinogen-induced rat mammary tumor model was applied, and results indicate that centrosome amplification is occurring early on during tumorigenesis, favoring growth advantage of cells and subsequent neoplastic outgrowth and tumor. Normal ductal epithelium and stromal cells displayed an expected complement of 1 to 2 centrosomes per cell; whereas, comparable cells in methylnitrosourea-treated animals displayed significantly elevated centrosome numbers. In tumors, 46% of cells showed more than 2 centrosomes/cell, and AurA expression levels coincided with higher centrosome numbers. Both centrosome numbers and AurA expression were permanently elevated. Errors in centrosome function were found to occur at a very early, premalignant stage prior to detectable lesions following treatment with methylnitrosourea (MNU), a condition that was not detected in mammary glands of rats made refractory to the carcinogen via pregnancy or estrogen and progesterone (E/P) treatment. Mammary glands of rats made refractory were protected against mammary tumors, centrosome amplification, and AurA overexpression.
Immunolocalization studies with an antibody to AurA demonstrated that the kinase has a function on the centrosome. The expression pattern for AurA is distinct, being localized to the separated, duplicated centrosomes throughout the cell cycle and to the mitotic spindle of dividing cells. A potential role of AuroraA might be to stabilize microtubules, which could lead to centrosome separation and microtubule-mediated chromosome movements at mitosis.
Our results also indicate that hormones influence kinase expression, independent from centrosome amplification, and progesterone had the major effect on AurA expression levels.
The AurA kinase might be 1 link between centrosome function and cell cycle progression. Investigating how increased expression levels, together with centrosome amplification, influence tumor formation and growth might provide a powerful tool for the assessment of prognostic factors in breast cancer.
Biological Effects of Peroxisome Proliferator-Activated Receptor Subtypes
−γ and −δ in Colorectal Cancer RAJNISH A. GUPTA AND RAYMOND N. DUBOIS, Departments of Medicine and Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
The peroxisome proliferator-activated receptor (PPAR) family of nuclear hormone receptors plays fundamental roles in the regulation of energy balance (7) . Putative endogenous ligands for PPARs include both polyunsaturated fatty acids and certain arachadonic acid metabolites. Given the important role that these types of lipid mediators have in the regulation of intestinal epithelial cell growth and differentiation, we have investigated the role of 2 PPAR subtypes, −γ and −δ, in the development of colorectal cancer.
The PPARγ subtype is strongly expressed in the postmitotic epithelial compartment of the normal human large intestine. Exposure of a panel of human colorectal cancer cell lines to PPARγ agonists leads to a decrease in cell growth that is associated with a partial G 1 arrest and increased levels of the cyclin dependent kinase inhibitor p21 (1) . Subsets of colon cancer cells lines were resistant to the growth inhibitory effects of PPARγ ligands. Genetic analysis of PPARγ in these cell lines revealed that they all harbored a point mutation at codon 422 of the ligand binding domain of the receptor. Further studies suggested this mutation leads to a loss of functional PPARγ due to a defect in the ability of the receptor to repress the transcription of some target genes in the absence of exogneous ligand. These findings, coupled with data from other investigators identifying other loss of function PPARγ mutations in colorectal cancer samples (6) , argues that the receptor has a tumor suppressive role during the development of colorectal cancer. Finally, microrray technology was used to understand the genomic response of intestinal epithelial cells exposed to PPARγ agonists. PPARγ selective target genes included proteins linked to regulation of cell growth, colon epithelial cell maturation, and immune modulation (2) . One gene rapidly and directly induced by PPARγ is Transforming Growth Factor β Clone-22 (TSC-22), a leucine zipper containing transcription factor that is capable of repressing gene transcription. Overexpression experiments using a dominant-negative TSC-22 suggests that PPARγ inhibits cell growth in part via activation of TSC-22.
Activation of PPARδ, in contrast to PPARγ , appears to promote the development of colorectal cancer. PPARδ was recently found to be a target of the β-catenin oncogene in colorectal cancer cells (4) . Moreover, genetic disruption of both PPARδ alleles in an established colorectal cancer cell line diminished the growth of the cells in vivo (5) We have found PPARδ to be overexpressed in a large percentage of colorectal tumors. In addition, in situ hybridization analysis of serial sections of colorectal tumors suggested that within a given colorectal cancer, regions expressing high levels of PPARδ also had high levels of the enzyme cyclooxygenase-2 (COX-2) (3). We have also shown that COX-2 derived prostacyclin is a potent endogeous ligand for PPARδ suggesting that COX-2 may in part promote colorectal cancer development by producing ligands that transactivate PPARδ. Microarray analysis was performed to identify gene expression changes after colorectal cancer cells are exposed to a high affinity, selective PPARδ agonist. Several genes involved in the regulation of cellular adhesion and apoptosis were induced by PPARδ and a current focus is to determine the role (if any) of these gene expression changes in the biological effects due to PPARδ activation in colorectal cancer cells. The alarming increase in prostate cancer incidence and its ranking as the second leading cause of cancer-related deaths in men lends an urgency to find new ways to treat and prevent prostate cancer (7) . The development of clinically evident prostate cancer spans several decades and is very common in men 60 years and older. Prostate cancer develops in distinct steps; each step being liable for additional genetic hits during progression (18) . Chemoprevention studies using either natural and/or synthetic compounds can exploit this slow multistep process of prostate cancer development to reduce cancer deaths by disturbing the various stages of cancer development (17) .
Most prostate tumors are initially androgen-dependent and thus, androgenablation is the standard therapeutic approach for treatment. Although as many as 80% of the patients respond initially to androgen ablation therapy, the duration of this response in most patients is transient (only 12-18 months) and tumors recur (4, 6, 8) . The emergence of hormone-refractory disease is generally a terminal event because of a lack of effective therapy for androgen-independent tumors (4, 6, 8, 16) . One cause of androgen-independence is the emergence of tumor cells that are able to grow either in the absence of, or in low concentrations of, androgens. Although the prostate gland is commonly considered as an androgen-dependent tissue, other nonandrogenic hormones such as prolactin, thyroid hormones, growth hormones, insulin and insulin-like growth factors, adrenal hormones, and estrogens also influence prostate development (5, 14) . In addition, androgens and estrogens regulate the stromal-epithelial interactions that in turn influence the growth and development of the prostate gland. Increasingly, the use of nonandrogenic signaling pathways has been linked to estrogen or estrogen metabolite modulated pathways (1-3, 10, 15) . Therefore, the use of antiestrogens or metabolites of estrogen may offer a new strategy in the treatment or prevention of prostate cancer. Along these lines recent results from 2 different groups including ours show that 2-methoxyestradiol (2-ME), an endogenous nontoxic estrogen metabolite, inhibits the growth of androgen-responsive and androgen-independent human prostate cancer cells through induction of apoptosis (11, 13) .
Subsequently we evaluated the potential of 2-ME in suppressing the development of prostate tumors using (a) subcutaneously implanted LNCaP prostate tumors in athymic nude mice and (b) in the TRAMP (transgenic adenocarcinoma of mouse prostate) model (18) (19) . In the LNCaP xenograft study, 25 mg/kg body weight of 2-ME resulted in complete regression of tumors in 7 out of 10 mice with no significant changes in body weight. Feeding 8-week-old TRAMP mice on a diet containing 2-ME (50 mg/kg) for 16 weeks showed a 50% reduction in the wet weight of the prostate. Histological analysis indicates that the glands from these animals are composed of columnar epithelium with round to oval nuclei with no indication of neoplasia in contrast to prostates from control animals that displayed epithelial proliferation in a characteristic cribriform pattern with hyperchromatic nuclei; mitotic figures and apoptotic bodies. The potential of 2-ME in reducing the development of invasive cancer will be discussed.
To obtain an insight into the molecular basis of 2-ME mediated growth inhibition, we have employed cDNA array analysis to search transcripts whose expression may be altered by 2-ME treatment. Our results indicate a possible role for the TNFα-signaling pathway in mediating 2-ME's antiproliferative activity. Preliminary experiments conducted using TNFRI neutralizing antibody blocked 2-ME mediated growth inhibition. Somatic stem cells divide with asymmetric kinetics to produce 2 daughter cells with different division capacities: 1 daughter divides to produce mature differentiated cells, and the other daughter maintains the division capacity of the parent without further differentiation. In 1975, John Cairns proposed that somatic tissue stem cells divide with a DNA segregation pattern distinct from differentiating cells (2) . Cairns postulated that when somatic tissue stem cells divide they continuously retain a set of chromosomes that contain parental DNA strands in order to minimize mutation retention. The retained old template DNA strands are referred to as "immortal strands." Previously, it has not been possible to test the immortal strand hypothesis directly (1, 3, 4, 6) . However, our laboratory recently developed cultured cells that divide with the asymmetric kinetics of somatic tissue stem cells (5, 7) . These specialized lines enabled us to investigate the immortal strand hypothesis in vitro.
We used equilibrium cesium choloride (CsCl) gradient analyses to evaluate DNA replication and segregation during asymmetric cell kinetics. The incorporation kinetics of the thymidine analogue bromodeoxyuridine (BrdU) determined by CsCl gradient analysis were as predicted for cells cycling with asymmetric cell kinetics. We found that in asymmetrically cycling cells DNA replication proceeds semiconservatively as in cells dividing with exponential cell kinetics. In contrast, results in segregation analyses of chromosomes in isolated cycling cells were quite different between cells dividing asymmetrically and control exponentially dividing cells. Isolated exponentially cycling mitotic cells showed the expected dilution of preexisting BrdU-labeled DNA strands after successive divisions in BrdU-free medium (A in Figure 1 ). Asymmetrically cycling mitotic cells retained a full complement of hemisubstituted chromosomes that contained preexisting BrdU after as many as 6 successive divisions in BrdU-free medium (B in Figure 1) . In these studies, we were surprised by the absence of normal unlabeled DNA expected to be found in the attached nondividing daughters of asymmetric cell divisions. Instead, we found DNA molecules that sedimented Methylation of cytosine in the context of a cytosine-guanine (CG) dinucleotide is an epigenetic modification that is critical for normal development, X chromosome inactivation, and allele-specific imprinting. Clusters of CG dinucleotides, called CpG islands, are present in the promoters and 5 regions of most housekeeping genes and approximately 40% of tissue-specific genes. Normally these CpG islands are unmethylated. However, during tumor development and progression, these CpG islands become methylated and this is correlated with transcriptional inactivation.
Analysis of aberrant promoter methylation in cancer has traditionally been performed on a gene-by-gene basis. To examine the overall patterns of methylation in cancer our laboratory uses a 2-dimensional electrophoresis system known as Restriction Landmark Genomic Scanning (RLGS). When performed with the methylation-sensitive restriction enzyme NotI to create the landmark, an RLGS profile results in a display of up to 2,000 CpG islands in a single assay. Previously we have shown that aberrant methylation in multiple tumor types shows nonrandom patterns, and we identified methylation events that are tumor type specific (1) . The overall hypothesis of our current study is that aberrant DNA methylation in acute myeloid leukemia (AML) is associated with inactivation of genes that are necessary for normal growth, differentiation, and/or death of hematopoietic cells, and that these epigenetic alterations play a key role in the molecular pathogenesis of AML.
Thirty-two pairs of diagnostic and remission bone marrow or peripheral blood samples from adults with de novo AML were obtained from the Cancer and Leukemia Group B Leukemia Tissue Bank and RLGS profiles were prepared (Figure 1 ). The profile from each diagnostic sample was compared to that patient's remission sample and the methylation changes were recorded. In an RLGS profile, the absence of a locus is indicative of methylation due to failure of the methylation-sensitive restriction enzyme (NotI) to cut the DNA, and lack of endlabeling of the NotI site. The level of methylation was highly variable among the diagnostic samples, ranging from 0-8.3% of the RLGS profile and extrapolated to involve up to 2,400 of the predicted 29,000 CpG islands in the genome. The frequency distribution of the methylation events indicates a nonrandom pattern ( p < 0.001). For example, the DRD4 gene located at 11p15 was methylated in 22 of 32 diagnostic samples (3) .
One of the strengths of using RLGS is the ability to clone novel methylated sequences for further analysis. Accordingly, one of the loci we have examined in more detail is the Cytochrome P450 1B1 gene (CYP1B1) on chromosome 2p21 (4). CYP1B1 is expressed in many normal tissues as well as tumors, and has been implicated in resistance to chemotherapeutics (2) . This locus was methylated in 6 of 24 AML patients with normal karyotypes, and 0 of 8 patients with either FIGURE 1.-RLGS profile of a bone marrow aspirate from a patient with AML. Directions of first-and second-dimension electrophoresis are shown, as well as approximate molecular weight markers. abnormal or undetermined karyotypes. Expression of CYP1B1 in nonexpressing leukemia cell lines can be induced by treatment with the demethylating agent 5-aza-2 -deoxycytidine. In order to more fully characterize the methylation pattern within the large CpG island spanning the 5 region and extending through exon 2, DNA from AML samples was treated with sodium bisulfite, which converts unmethylated cytosines to uracil (and then to thymine in subsequent PCR reactions), while leaving methylated cytosines unchanged. The bisulfite sequencing analysis of 58 CG dinucleotides revealed that diagnostic samples had both methylated and unmethylated alleles of the CYP1B1 promoter, and a consistently higher degree of methylation in the body of the gene compared to remission samples. Immunohistochemistry and in situ hybridization on bone marrow samples show varying levels of CYP1B1 in AML blasts. Methylationspecific PCR in situ hybridization targeted to the promoter region will allow us to correlate promoter methylation levels with the level of protein.
CONCLUSION
RLGS is a useful technique for the assessment of global methylation patterns and the identification of novel methylated sequences. AML is characterized by varying degrees of nonrandom aberrant DNA methylation, with some genes being methylation at high frequency in diagnostic samples. Importantly, because demethylating agents are now being used in clinical trials for the treatment of hematologic malignancies, a better understanding of aberrant methylation in these diseases is essential. Promoter methylation of CYP1B1 is present in AML, and the density of cytosine methylation increases in the body of the gene. The role of CYP1B1 methylation in the pathogenesis and/or progression of AML is under investigation. Our recent development of cultured mammalian cells that divide with asymmetric cell kinetics (6, 8, 9) , attributed to adult stem cells in vivo, allowed us to design direct tests of a long-standing hypothesis in cancer biology. Referred to as the immortal DNA strand hypothesis (ISH), it states that adult somatic tissue stem cells (SSCs), that divide with asymmetric cell kinetics, repeatedly inherit an entire complement of chromosomes that contain the same parental template DNA strands from one generation to the next. This coordinated, nonrandom, pattern of mitotic chromosome cosegregation was originally proposed by John Cairns in 1975 as an essential protective mechanism against the development of human neoplasia (1) . Selective retention of immortal DNA templates would allow SSCs to avoid fixation of carcinogenic gene mutations that arise from DNA replication errors.
Demonstration of an
The immortal strand hypothesis (ISH) is illustrated in Figure 1 . The diagram depicts the segregation fate of chromosomes with immortal parental template DNA strands through semiconservative DNA replication and one asymmetric stem cell division. There are many possible ways that newly synthesized chromosomes may assort between any 2 new daughter cells. In the traditional view of mitosis, random chromosome assortment occurs as a consequence of FIGURE 1.-The immortal strand hypothesis (ISH). Somatic stem cells (SSC) dividing with asymmetric cell kinetics possess chromosomes that contain immortal template DNA strands (shown in red, striped). These chromosomes are selectively cosegregated into the next-generation SSC. a) An SSC containing chromosomes with immortal template strands replicates its DNA semi-conservatively. b) During mitosis there are many possible ways to independently segregate the resulting chromosomes. c) The immortal strand mechanism assures that all of the immortal template DNA strands (red, striped) are always cosegregated into the new SSC. independent segregation (Figure 1b) . In contrast, the ISH proposes that a full complement of immortal parental DNA strands continuously cosegregates to long-lived SSCs (Figure 1c) . Therefore, all mutations that arise due to DNA replication errors, either immediately segregate to the short-lived nonstem cell daughter ("transit cell" in Figure 1 ) or do so to the next nonstem cell daughter produced by the subsequent stem cell division.
An explicit precept for the ISH is that stem cells that retain immortal DNA strands divide with deterministic asymmetric cell kinetics, producing at each stem cell division a new stem cell and a transit cell progenitor of terminally differentiating tissue cell lineages. Recognition of the ability of SSCs to maintain their number while renewing diverse tissue cells led to the concept of asymmetric stem cell kinetics (2, 4, 5) . The ability of mammalian cells to cycle with deterministic asymmetric cell kinetics, as predicted for SSCs, was first shown with cultured human and murine cells (8) . This was accomplished with cell lines engineered for controlled physiological expression of the p53 tumor suppressor protein (6) (7) (8) (9) . Subsequently, deterministic asymmetric cell kinetics have been described for stem cell-enriched human bone marrow cells (3) and presenescent human and murine fibroblasts (6) . Having cultured cells that modeled the unique asymmetric cell kinetics proposed for SSCs in vivo allowed us to investigate the existence of immortal DNA strands by direct methods.
Using several independent methods-including flow cytometry, metaphase chromosome Hoechst-fluorescence analysis, and analysis of bromodeoxyuridine-labeled DNA segregation-we have now demonstrated the selective cosegregation of chromosomes containing immortal template DNA strands in mammalian somatic cells that cycle with asymmetric kinetics. Beyond providing direct support for a novel anticancer mechanism in adult SSCs, our findings also raise provocative ideas regarding the nature of human aging. A remarkable predicted corollary of the immortal strand hypothesis is that the chromosomes of SSCs in adult tissues will contain DNA strands present since birth. Unrepaired damage that accumulates over time in immortal strands could compromise stem cell function and viability and, thereby, contribute to tissue aging, as well as cancer. βTrCP and HOS are closely related F-box proteins, which play key roles in ubiquitination and degradation of β-catenin and IκB through associating with those phosphorylated substrates and recruiting SCF E3 ubiquitin ligase [reviewed in (2) (3) (4) 6] . The Wnt signaling pathway plays a key role in normal embryonic development and in malignant transformation of many types of human cells [reviewed in (4, 5) ]. Here we report that activation of Wnt signaling pathway induces βTrCP levels but inhibits expression of HOS. Similar disparity is likely to exist in human colorectal tumors.
Wnt Signaling Differentially Regulates
β-catenin/Tcf signaling elevates the expression of βTrCP mRNA and protein in a manner, which is dependent on Tcf-mediated transcription. The increase in βTrCP apparently occurs via a stabilization of its mRNA. Induction of βTrCP expression by βcatenin/Tcf pathway results in an accelerated degradation of the wild-type of β-catenin, suggesting that the negative feedback loop regulation may control β-catenin/Tcf pathway. This signaling also upregulated NF-κB transactivation without affecting the activity of IκB kinase, thereby establishing the importance of the maintenance of βTrCP level for interaction between β-catenin/Tcf and NF-κB signaling.
As it has been shown that Wnt exerts some of its effects in a β-cateninindependent manner via JNK pathway (1), we investigated whether the activation of JNK signaling can actually regulate the abundance and activity of βTrCP. We have found that this "noncanonical" Wnt signaling, through the activation of JNK, also induces an increase in the steady-state levels of βTrCP mRNA and protein levels in human cells. Activation of stress-activated protein kinases JNK by forced expression of constitutively active mutants of JNKK2 and MKK6 (but not MEK1 or IKKβ) also leads to accumulation of βTrCP. Transcription of βTrCP gene is not required for JNK-mediated induction of βTrCP. A synergistic effect of stimulation of IKK and JNK on the transcriptional activity of NF-κB was observed.
In the NIH 3T3 cells, which express HOS, but not βTrCP, Wnt/β-catenin signaling leads to inhibition of HOS promoter activity and NF-κB-driven transcription as well as to stabilization of β-catenin. These results indicate that expression and activities of HOS are negatively regulated by Wnt/β-catenin pathway.
Our data suggest that, despite structural and functional similarity between βTrCP and HOS, those 2 F-box proteins are regulated by Wnt/β-catenin pathway in an entirely opposite manner. These differences in the regulation may determine alternative responses to signal transduction events, depending on which of those F-box proteins are expressed in these very cells. Sanguinarine, a benzophenanthridine alkaloid, has been shown to induce cell death by apoptosis and oncosis at different concentrations. When exposed to sanguinarine at concentrations of 1.5 µg/ml and 12.5 µg/ml for 2 hours, k562 human erythroleukemia cells displayed the morphologies of 2 different modalities of cell death: at 1.5 µg/ml the classical morphology of apoptosis in over 96% of cells and at concentrations of 12.5 µg/ml, the morphology of single blister formation (blister cell death or BCD)-a form of oncosis, in over 90%. At the intermediate sanguinarine concentration of 6.25 µg/ml, the 2 morphologically distinct phenomena of apoptosis and oncosis were interphased by diffuse swelling of cells that may represent a different form of oncosis.
Sanguinarine-Induced Apoptosis and
Sanguinarine-treated K562 cells, when analysed by western blot, showed significant increase in expression of the pro-apoptotic Bax protein in apoptosis, but not in BCD. On the other hand, the anti-apoptotic protein Bcl-2 was found to inhibit both sanguinarine-induced apoptosis and BCD. Thus, the Bax/Bcl-2 ratio was found to correlate with the susceptibility of cells to apoptosis but not BCD. Furthermore, we have shown that sanguinarine-induced apoptosis leads to caspase 3 activation and cleavage of PARP and other caspase 3 substrates; whereas, the blocking of this pathway leads to oncosis/ BCD. Recent reports in the literature have shown that the activation of certain cell surface proteins, including phospholipase A 2 and Porimin, can trigger oncosis.
We also show that aurin tricarboxylic acid (ATA), a DNA general endonuclease inhibitor, efficiently prevented DNA nicking and inhibited apoptosis almost completely and oncosis/BCD by 30-40% as evident from the results of quantitative morphology and 51 Cr release. This finding is puzzling, as oncosis/BCD, unlike apoptosis, is not associated with DNA nicking. Recently, however, it has been suggested that apoptosis may share common molecular pathways with other types of cell death at the early stages. These pathways are thought to share some, but not all, the characteristics of classical apoptotic pathways. Our results with ATA show that apoptosis and oncosis/BCD may indeed share common pathways, especially at the early stages. Molecular classification of cancer promises to lead to cancer prevention, early diagnosis, and the development of optimal treatment protocols (4). Histologically similar tumors may result from substantially different genetic changes; the ability to capture these underlying genetic changes will be essential for the development of new tools. Furthermore, molecular fingerprints may prove critical in diagnosis of clinical cases where traditional methods have failed; 1 example is the 'unknown primary' case where a metastatic lesion is detected but the primary site of cancer is not known.
Gene Expression Fingerprints for
The first and crucial step in molecular classification of cancer is the establishment of organ-specific expression patterns. Several groups are utilizing genomewide expression profiling approaches to identify robust sets of genes that can be used to classify human carcinomas based on the tissue (1-3) . We have identified an initial set of tissue-specific signatures by microarray profiling of tumor specimen from 8 classes of adenocarcinomas (breast, colon, esophageal junction, kidney, lung, ovary, pancreas, and stomach) and colon cancers that have metastasized to the liver.
Expression profiling was performed on 10 patient samples per tumor class using cDNA microarrays. 32,448 clone inserts were PCR-amplified and spotted on aminosilane-coated slides to make the cDNA arrays. Total RNA was reverse transcribed into cDNA in the presence of 5-aminoallyl-dUTP, and Cy3 and Cy5 dyes were covalently coupled to the incorporated aminoallyl linker. Each tumor sample was cohybridized with the reference sample constructed from a pool of three cell lines in a set of flip-dye replica experiments (180 hybridizations total). Arrays were normalized individually using local linear regression (lowess) (5) . A relatively simple approach was developed to check the flip-dye replicas and filter out genes that have one or both of the replica spots of poor quality. Tissue-specific molecular fingerprints were extracted from the dataset using both an unsupervised linear algebra approach and a supervised neural network algorithm. Real RT-PCR was performed on 5 marker genes for each tissue to validate microarray data.
Examination of the molecular fingerprint (Figure 1) indicates that robust sets of molecular markers are identified for each tumor class. In addition, adenocarci-FIGURE 1.-A hierarchical clustering tree showing tissue-specific molecular fingerprints of human carcinomas extracted from the microarray data using a linear algebra approach. noma samples from the same tissue cluster together with only a few exceptions, and tissues that are expected to have similar assortment of genes expressed, such as the ovary and the breast, cluster more closely. Furthermore, colon metastases are closest to the colon primary tumors in the hierarchical tree. This finding provides preliminary evidence that tumors carry gene expression fingerprints from the primary site to the metastatic lesion. Hybridization assays examining metastases coming from a number of known primary sites (breast, lung, ovary, etc) are underway. Fingerprints established using adenocarcinomas and metastatic tumors of known origin will be used in the near future to attempt to classify 'unknown primary' metastases.
Presented at this conference will be:
1. tissue-specific cancer classifier extracted from expression profiles of primary and metastatic tumors, 2. a general data analysis protocol we have developed for cDNA array data, and 3. data on the selection of an optimal reference pool consisting of RNA derived from cell lines.
indicate specific interactions of BLM, WRN, and p53 with HJ. Super-shift assays showed further retardation of the BLM-, WRN-, and WTp53-X-junction complex verified by Western blotting with the antibodies specific for these proteins. Electron microscopic visualization of p53-HJ interaction confirmed our observations. The 248Wp53 showed slightly lower binding affinity than the WTp53. When compared with the WTp53, the 273Hp53 mutant not only had reduced binding to DNA, but also had lost the specificity of the crossover point. The RuvA protein competed efficiently with WRN, or p53 for binding to the X-junction. Consistent with a previous report (4), similar results were seen with BLM. These data indicate that p53, BLM, and WRN recognize the DNA crossover region of the HJ. BLM and RAD51 form a complex and colocalize to nuclear foci in cells arrested in S-phase using either aphidicolin or hydroxyurea (5, 6) . The effects of p53 on BLM unwinding of HJ presented here suggest that activated p53 may be involved in the process in vivo. About 45% of the aphidicolin-treated cells contained ser15 phospho-p53 nuclear foci. Confocal analysis of pixels indicated that 63% and 39% of the ser15 phospho-p53 foci colocalized with BLM or RAD51, respectively. These in vivo colocalization results were extended by performing co-immunoprecipitation experiments. About 10% of the cellular p53 binds to either BLM or WRN. The binding affinities of WT and mutant p53 to BLM and WRN were determined by both Far Western analysis and ELISA. WTp53 and 248Wp53 bound in a dose-dependent manner, and with similar affinities, to both BLM and WRN. In contrast, 273Hp53 showed a relatively weak level of binding to either BLM or WRN. These data indicate that p53 plays a role in a DNA recombinational repair pathway that also includes BLM and RAD51.
The C-terminus of p53 is both required for binding to BLM or WRN and is posttranslationally modified. When p53 is activated, the phosphorylated serines at 376 and 378 found in latent p53 are dephosphorylated by an unknown phosphatase. Therefore, we determined whether modification of the C-terminus of p53 would alter its ability to modulate BLM and WRN helicase activities in a model in vitro system. Protein kinase C (PKC) phosphorylates p53 in vitro at ser376 and ser378 within the PAb421 antibody epitope, thereby reducing PAb421 reactivity. Protein phosphatase PP1 dephosphorylates the PKC-reactive site in p53. The PKC-phosphorylated p53 protein exhibited reduced inhibition of BLM or WRN helicase activity relative to unmodified p53, whereas dephosphorylation of PKC-treated p53 protein by PP1 restored its activity. In addition, PAb421, but not DO-1, an antibody to the N-terminus of p53, also blocked the inhibitory effect of p53 on BLM and WRN helicase activities. In correspondence with the results of the helicase assays, modifications of the recombinant GSTp53 fusion protein, through either PAb421 antibody or PKC phosphorylation, attenuated its ability to bind to BLM or WRN protein. The p53 peptide (residues 373-383) exhibited concentration-dependent inhibition of BLM and WRN helicase unwinding of the X-junction. In contrast, p53 peptide phosphorylated at ser376 (P1) or ser378 (P2) was noninhibitory, even at high concentrations. Taken together, we conclude that the C-terminus of p53 at residues 373-383 is required for its interaction and modulation of BLM and WRN unwinding of HJ.
The data from both in vitro and in vivo experiments presented here indicate that activated p53 may regulate the DNA recombinational repair pathway. Consistent with previous reports by us and others that WRN copurifies with a DNA replication complex and binds to p53, p53 may regulate the antirecombinase functions of these human RecQ helicase family members that are critical for the maintenance of genomic stability during DNA metabolism. FIGURE 1.-Cells were plated at 1-2 × 10 5 cells/well in 12-well plates, allowed to adhere overnight, then treated with adenovirus at the indicated MOI (MOI used) for 4 h in Opti-MEM. Media was then changed to standard media, and MTT applied to duplicate wells after 3 days (2 days for C3L5 and TS/A) and absorbance measured. % growth inhibition was calculated by % = [1-mean abs(Ad)/mean abs(Mock)] × 100. MOI needed was the MOI of Ad-EGFP that was needed for >95% green cells. All cells at MOI used had strong expression of IRF-1 by Western blot. cell lines, C127I and NmuMG, and the human mammary epithelial cell line MCF10F, were not inhibited despite ∼100% expression as seen by Ad-EGFP and confirmed high expression of IRF-1 by Western blot.
As seen in Figure 2 , apoptosis appears to be a mechanism of cell death mediated by AdIRF-1 seen in at least two mouse breast cancer cell lines, C3-L5 and TS/A. We have further confirmed the role of apoptosis using Z-VAD-fmk, a pan-caspase inhibitor, which decreases the apoptotic and necrotic fraction in AdIRF-1 treated cells (Figure 2) , and by demonstrating significant PARP cleavage in AdIRF-1 infected C3-L5 cells (data not shown). Finally, we have found that IRF-1 overexpression in breast cancer cells using AdIRF-1 prevents tumor formation in vivo in syngeneic mice. As seen in Table 1 , ex vivo infection with 200 MOI of Ad-IRF-1 prevented tumor formation in 4 out of 5 mice treated, and this was statistically significantly different from both Ad-5 treatment and mock treatment, for which 100% of mice developed tumors. However, in athymic nude mice Ad-IRF-1 did not prevent growth of tumors, which implies that a T-cell mediated immune response is involved in eradication of Ad-IRF-1 transfected C3L5 breast cancer cells, and that the apoptotic and growth inhibitory effect of IRF-1 alone fails to eliminate all breast cancer cells.
In conclusion, IRF-1 can suppress breast cancer cells in vitro and in vivo, and this appears to be mediated both by apoptosis and enhanced immunogenicity. Induction of IRF-1, whether directly, such as with gene or molecular therapy, or indirectly, such as by cytokines or retinoic acid, may useful in the treatment of breast cancer.
